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Introduction and outline o f dissertation
Introduction
In the majority o f patients with hypertension the cause is not known. In the last few years 
several studies have suggested a role for the enzyme 11 ß-hydroxysteroid dehydrogenase 
(11 ß-HSD) in the pathogenesis o f hypertension. In this paper we review the function of 
this enzyme under normal conditions and in various forms of secondary hypertension like 
the Apparent Mineralocorticoid Excess (AME) syndrome and licorice-induced 
hypertension. In addition, the potential role of 11 ß-HSD in the pathogenesis of 
glucocorticoid and, in particular, primary hypertension is discussed. Furthermore the 
relation between primary hypertension and the activity o f 11 ß-HSD in cardiovascular 
tissues, the central nervous system and in the placenta will be reviewed.
Physiological function of 11ß-hydroxysteroid dehydrogenase
The 11 ß-HSD isozymes catalyze the dehydrogenation of the naturally occurring 
glucocorticoids cortisol and corticosterone to their inactive 11-keto products cortisone 
and 11-dehydrocorticosterone as well as the reverse reductive reaction. The isozymes are 
present in many tissues, but their activity is not uniformly distributed1. Originally 11 ß- 
HSD was considered to be one single enzyme. Later two independent isozymes were 
identified, called 11ß-HSD1 and 11ß-HSD22.
The isozyme 11ß-HSD1 is ubiquitously present, e.g. in liver, lungs, gonads, hippocampus, 
cerebellum, pituitary gland and also in the proximal renal tubules1;3;4. Its cDNA has first 
been cloned and sequenced in the rat5 and later also in man6. The gene for 11ß-HSD1 has 
been located on chromosome 16. 11ß-HSD1 is NADP(H)-dependent and catalyzes both 
dehydrogenation and reduction7;8. In vitro both reactions are inhibited by glycyrrhetinic 
acid (GA), an important compound of licorice, and by its hemisuccinate carbenoxolone. 
A slightly higher GA concentration is necessary for inhibition of reductase- than for 
inhibition of dehydrogenase-activity9. In the liver 11ß-HSD1 predominantly acts as a 
reductase, converting cortisone to cortisol (see fig. 1).
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Fig. 1 The cortisol-cortisone shuttle
F = cortisol 1 = llß-HSDl
E = cortisone 2 = llß-HSD2
In the kidney, cortisol is converted to inactive cortisone by 11ß-HSD2, and in the 
liver cortisone is converted to cortisol by 11ß-HSD1 (cortisol and cortisone 
interconversion is indicated by dashed arrows). Cortisol has affinity for the renal 
mineralocorticoid receptors (as indicated by the dotted arrow), but in normal 
circumstances binding of cortisol to these receptors is prevented because of fast 
conversion of cortisol to cortisone by 11ß-HSD2. When activity o f this isozyme is 
decreased, for instance by inhibition by glycyrrhetinic acid or carbenoxolone, 
cortisol will bind to the mineralocorticoid receptors.
The second isozyme, 11ß-HSD2, is a high affinity NAD-dependent enzyme that is highly 
expressed in mineralocorticoid target tissues such as renal cortex, in particular distal 
tubules and collecting ducts9, and medulla8, rectal and sigmoid colon8, salivary glands10 
and sweat glands11. It is also present in the adrenals and in the organs o f the 
female reproductive system (ovary, uterus, and placenta)12;13. The gene coding for 11 ß- 
HSD2 activity, HSD11B2, has been cloned in sheep14, mouse15, rabbit16, rat17, and in man 
where it is located on chromosome 1618. While the isozyme has generally been located in 
the microsomes, recent studies have also demonstrated presence of 11ß-HSD2 in cell 
nuclei19;20. This isozyme has mainly dehydrogenase activity and is already active at very 
low cortisol concentrations. The Michaelis-Menten constant for 11ß-HSD2 is 50-60 
nmol8;13, compared to 17 p,mol for 11ß-HSD121.
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11ß-HSD2 plays a key role in regulating mineralocorticoid activity of glucocorticoid 
hormones. In-vitro experiments have shown that cortisol and aldosterone have similar 
affinities for mineralocorticoid receptors (MR)22, so their functional aldosterone selectivity 
in vivo is apparently not mediated by the receptor structure. In vivo MRs are protected from 
exposure to cortisol by the isozyme 11ß-HSD2. This isozyme rapidly metabolizes the 
active mineralocorticoid cortisol to its inactive metabolite cortisone (see fig 1). The 
physiological relevance of this enzyme for the regulation of blood pressure and 
potassium balance was demonstrated in studies in patients with apparent 
mineralocorticoid excess (AME)23 and in licorice-induced hypertension24. In these patients 
renal activity o f 11ß-HSD2 is decreased. In a recently published in vivo study on renal 
electrolyte transport in anesthesized rats it was demonstrated that inhibition of 11ß-HSD2 
activity resulted in lowered fractional Na+ excretion and increased K+ secretion in the 
distale tubule25, confirming that changes following inhibition of 11 ß-HSD2 activity occur 
in the specific area where the mineralocorticoid receptors are located.
In studies on renal 11ß-HSD2 activity in humans, analysis of urinary corticosteroid 
excretion played an important role. In the kidney cortisol is metabolized to cortisone. 
Cortisol can be reduced to tetrahydrocortisol (THF) and allo-tetrahydrocortisol (allo- 
THF), and cortisone to tetrahydrocortisone (THE) (figure 2: left panel). Therefore 
decreased renal 11ß-HSD2 activity will result in an increased urinary (THF+allo- 
TH F)/TH E ratio and access o f cortisol to the renal MR (fig. 2: right panel). Some of the 
studies involved will be discussed in more detail below.
Conversion of cortisol to cortisone has also been demonstrated in cardiovascular cells26. 
In rats, activity of 11 ß-HSD is found in cardiac myocytes and fibroblasts, and in vascular 
smooth muscle cells, but not in endothelial cells27-29. The enzyme activity is NADP(H)- 
dependent and bidirectional30, indicating type 1 isozyme activity. While cardiac activity of 
11 ß-HSD type 1 is high in species in which corticosterone is the predominant 
glucocorticoid (rats, pigs and rabbits), it is low in species in which cortisol is the major 
glucocorticoid (humans and dogs)31. Indeed, in human cardiomyocytes activity of 11 ß- 
HSD is mainly dependent on NAD, suggesting activity o f type 2 isozyme32. Both vascular 
smooth muscle cells and skin arterioles in humans express 11ß-HSD211;33. Recent studies
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in human blood vessels do demonstrate also the presence of 11ß-HSD2 in vascular 
endothelial cells34. The exact function of 11ß-HSD2 in these cells remains to be 
elucidated.
Specific binding of aldosterone to MRs has been found in human heart35 and cultured 
human arterial smooth muscle cells36. In more detailed immunohistochemical studies, 
MRs were localized in cardiac myocytes and fibroblasts, vascular smooth muscle cells and 
in cardiac and vascular endothelial cells37;38. These MRs can be activated by aldosterone. 
This hormone is not solely produced by the adrenals. Recently, synthesis o f aldosterone 
has also been described in rat mesenteric arteries39 and cultured human vascular 
endothelial and smooth muscle cells40. Vascular aldosterone production could be 
increased by Angiotensin II and potassium, and decreased by angiotensin-converting 
enzyme (ACE) inhibition. Although adrenocorticotropic hormone (ACTH) also regulates 
adrenal aldosterone synthesis, it does not affect vascular aldosterone production41. This is 
explained by the finding that mitochondrial P-450scc (the enzyme that regulates 
conversion of cholesterol to pregnenolone in an ACTH-dependent way) is absent in 
vascular cells, while it is the key enzyme for regulating corticosteroid synthesis in the zona 
glomerulosa of the adrenals42.
It has been demonstrated that aldosterone mediates rapid effects in smooth muscle cells. 
These effects are not mediated by classic genomic pathways, but by rapid non-genomic 
pathways that stimulate Na+-H+ ATPase activity43;44, inositol triphosphate production43 
and release o f intracellular calcium45. Recently it was demonstrated that cortisol also 
mediates similar rapid effects in smooth muscle cells. This effect o f cortisol only 
occurred when activity o f 11ß-HSD2 was inhibited46. This suggests that the activity of 
vascular 11ß-HSD2 is crucial in maintaining the specificity of the rapid effects of 
aldosterone.
Activity o f 11 ß-HSD has also been demonstrated in the central nervous system. In studies 
in rat brains the highest NADP-dependent (type 1) enzyme activity was described in the 
hippocampus, cortex, pituitary, hypothalamus, brain stem and spinal cord47;48. Expression 
of 11 ß-HSD type 2 mRNA was clearly found in the commissural portion of the nucleus 
tractus solitarius, the subcommissural organ and the ventrolateral and ventromedial
6
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Fig. 2
a) MR
b)
Under physiological conditions (a) cortisol is metabolized to cortisone by 11 ß- 
hydroxysteroid dehydrogenase type 2 (11ß-HSD2). As a consequence the 
mineralocorticoid receptor (MR) will not be exposed to relevant cortisol 
concentrations. When 11ß-HSD2 activity is reduced, either congenitally (AME 
syndrome) or by inhibition by glycyrrhetinic acid, cortisol is not completely 
metabolized to cortisone and therefore activates the MR (b). Urinary excretion of 
cortisol and its tetrahydrometabolites (THF and allo-THF) is increased, while 
excretion of cortisone and its tetrahydrometabolite THE is decreased. This results 
in increased ratio o f (THF+allo-THF) to THE, reflecting decreased renal activity of 
11 ß-HSD2.
5ared = 5a-reductase; 5ßred = 5ß-reductase.
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hypothalamus49, areas in the brain known to be involved in cardiovascular regulation50. It 
is not clear whether MRs in the brain are protected by 11 ß-HSD2. Although the isozyme 
is present in the brain and administration of inhibitors o f 11ß-HSD2 activity results in 
hypertension, intracerebroventricular (icv) infusion of corticosterone does not increase 
but decrease blood pressure, and blood pressure does not change during administration of 
RU28318, a specific mineralocorticoid antagonist51;52.
Finally, presence of 11ß-HSD2 mRNA and isozyme activity have been demonstrated in 
the placenta o f rats and humans12;13. In contrast to the 11ß-HSD2 expressing tissues that 
have been discussed previously, mineralocorticoid receptors have not been demonstrated 
in the placenta. Therefore the isozyme does not serve as a protector against cortisol 
mediated activation of MR, but it regulates fetal exposure to maternal glucocorticoids53.
Apparent Mineralocorticoid Excess Syndrome
In the 1970s a new hypertensive syndrome consisting of hypertension, hypokalaemia, low 
renin activity and low aldosterone production was described23. Additional clinical features 
were short stature, polyuria, polydipsia and failure to thrive. More than 20 cases with this 
syndrome, mainly children, have been published54;55. Sometimes hypertensive retinopathy 
and cardiomegaly were already discovered at a very young age, and four patients died 
before the age of 15 as a result of complications o f hypertension or hypokalaemia54;56. 
Clinical and biochemical findings suggested overproduction of an (unknown) adrenal 
mineralocorticoid, but circulating cortisol was normal and no other steroid could be 
identified. Therefore the syndrome was described as the Apparent Mineralocorticoid 
Excess (AME) syndrome57. Administration of hydrocortisone (=cortisol) aggravated the 
condition58, while dexamethasone administration (suppression of adrenocorticotropic 
hormone (ACTH)) normalized hypokalaemia and blood pressure. The AME syndrome 
responded to spironolactone, a MR blocker. Amiloride had some effect but potassium 
supplements were still required59. Further studies showed that conversion of plasma 11a- 
[3H]-cortisol to tritiated water and cortisone was reduced and urinary (THF+allo- 
TH F)/TH E ratio was increased60. These data suggested that the syndrome was caused by 
decreased activity o f 11 ß-HSD, resulting in activation of the MR by cortisol. This form of
8
Introduction and outline o f dissertation
AME was called type 1. Apart from the decreased 11 ß-HSD activity it seems that 5ß- 
reductase activity (measured by ratio o f 5a- (including 5a-THF) to 5ß-metabolites in 
urine) is also decreased in this syndrome56. The clinical relevance of the decreased 5ß- 
reductase activity is however not clear.
In recent years studies on HSD11B2, the gene coding for 11ß-HSD2 activity, confirmed 
that AME type 1 syndrome is caused by reduced 11ß-HSD2 activity. To date, more than 
20 mutations in the gene encoding for 11ß-HSD2 activity have been described (see e.g. 
Ferrari et a/.61). Almost all mutations have been found in exons 3-5. These mutations 
result in a premature stop codon or a change in aminoacid sequence. When genes carrying 
the mutations were expressed in cultured chinese hamster ovary cells the activity o f 11 ß- 
HSD2 in these cells was considerably decreased, in most cases to less than 5% of normal. 
In addition, one mutation in codon 2 has been described that affects the cofactor-binding 
domain of 11ß-HSD262. The inheritance of AME type 1 is autosomal recessive. Studies in 
parents o f a child with AME type 1 revealed that in the heterozygote state blood pressure 
is not increased and urinary steroid profiles were normal63. The gene for 11ß-HSD1 is 
normal in patients with AME type 164. The AME type 1 syndrome is one of the few 
examples o f human hypertension caused by a single gene defect.
Ulick and colleagues described a second form of AME, called AME type 2. In four 
patients with this variant no evidence for severely impaired activity of 11 ß-HSD2 or 5ß- 
reductase was found65. As the total amount o f THF + allo-THF in urine was low 
compared to urinary cortisol it was concluded that in these patients the metabolic 
inactivation o f cortisol by ring A reduction is impaired66. Walker et al. have suggested that 
in AME type 2 both 11 ß-hydroxysteroid dehydrogenase and 11 ß-hydroxysteroid 
reductase activity are reduced67. It has been demonstrated that plasma half-life for 11a- 
[3H]-cortisol, which is prolonged in patients with AME type I, is also prolonged in 
patients with AME type II68. Molecular analysis in a large family with type II AME 
revealed a mutation in codon 279 in HSD11B2, resulting in a relatively mild reduction of 
maximum 11 ß-HSD2 activity by about 35% of normal69.
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An other inheritable hypertensive syndrome with signs o f hypermineralocorticoid activity 
that can also be relieved by dexamethasone is glucocorticoid-remediable aldosteronism 
(GRA)70;71, now also known as familial hyperaldosteronism I72. In contrast to the AME 
syndrome, aldosterone secretion rate is increased in GRA and is primarily regulated by 
ACTH73. Severe hypertension is most commonly discovered in infancy or early 
adulthood. Usually many family members are affected due to autosomal dominant 
inheritance74. GRA is probably caused by a mutation in chromosome 8q, resulting in 
fusion of the regulatory region of 11ß-hydroxylase to the coding sequences of aldosterone 
synthase75. Thus aldosterone synthase is expressed in the ACTH regulated zona 
fasciculata, explaining the increased synthesis of aldosterone and two abnormal adrenal 
steroids, 18-oxocortisol and 18-hydroxycortisol76.
Licorice-induced hypertension
Excessive consumption of licorice or its active component GA may result in severe 
hypertension, hypokalaemia and other signs o f mineralocorticoid excess77. In some cases 
the hypokalaemia has resulted in rhabdomyolysis and/or tetraparesis78;79. In the 
Netherlands the average yearly licorice consumption is 2.2 kg per person (approximately 
450 mg GA), but individual consumption probably varies considerably, just as reported in 
Denmark80 and New Zealand81. The effects o f licorice become visible after 3-10 days and 
are usually reversible in several weeks. However, suppression of the renin angiotensin­
system has been described for up to four months after cessation of consumption79. Just as 
in the AME syndrome, licorice-induced hypertension and hypokalaemia are cortisol- 
dependent and respond to spironolactone, an aldosterone receptor antagonist82. Further, 
consumption of GA or licorice results in increased cortisol/cortisone ratio in plasma and 
urine24;83. This suggested that licorice-induced hypertension is caused by decreased 11 ß- 
HSD2 activity. In in vitro studies both GA and carbenoxolone inhibit activity o f this 
isozyme in a dose-dependent manner. In rat kidney microsomes, 70% inhibition of 
isozyme activity was found after addition of 20 nM GA or 16 nM carbenoxolone. 
However, in intact renal cortical tubules substantially higher GA concentrations (10-4 to 
10-6 M) were required for 11ß-HSD2 inhibition84.
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In a study in volunteers no change of plasma potassium, aldosterone and PRA was found 
during GA intake of 217 mg/day, but a decrease o f these parameters was clearly present 
at 813 mg/day. Increased blood pressure was only found in 2 out o f 12 volunteers in the 
high dose group85. This study suggests that licorice-induced effects in humans are dose- 
dependent, but a direct relation between plasma GA concentration and changes in blood 
pressure, plasma cortisol/cortisone ratio and potassium has not been demonstrated. A 
review by St0 rmer et al. shows that adverse effects of licorice have been reported after 
daily GA intake ranging from 0.01 to 4 grams. A daily intake of 10 mg GA (±50 g licorice) 
is regarded as a safe dose for most healthy adults86. The wide variability of GA effects 
may be explained by individual variation in the effects o f mineralocorticoids, the renal 
mineralocorticoid escape87;88, variation in bioavailability o f GA or by individual variation 
in sensitivity o f 11ß-HSD2 to GA. In conclusion, licorice consumption can result in 
decreased 11ß-HSD2 activity, resulting in hypertension and hypokalaemia due to cortisol­
mediated activation of the MR.
Activity of 11ß-HSD in glucocorticoid induced hypertension
Hypertension occurs in approximately 75 % of patients with Cushing’s syndrome89. In 20 
% of patients treated with oral glucocorticoids hypertension was found90, the incidence 
o f hypertension probably being dose-dependent. Several studies found an increased 
urinary ratio o f (THF+allo-THF)/THE in patients with Cushing’s syndrome, suggesting 
decreased 11ß-HSD2 activity. The ratio was highest in patients with Ectopic ACTH 
syndrome91. Further, infusion of ACTH in dexamethasone-treated normal volunteers 
resulted in increased cortisol/cortisone ratio. However, a direct inhibitory effect of ACTH 
on 11ß-HSD2 could not be confirmed by in vitro experiments in human kidney slices92. 
More recently it was suggested that the increase of the serum cortisol/cortisone ratio after 
ACTH stimulation may be caused by an increase o f conversion of cortisone to cortisol by 
11ß-HSD193. Further it was shown that while the (THF+allo-THF)/THE ratio was 
increased in patients with Cushing’s syndrome, the total TH E excretion was not 
decreased, but increased, suggesting that 11ß-HSD2 is quite active91;94. Therefore it seems 
that in patients with Cushing’s syndrome absolute 11ß-HSD2 activity is not decreased,
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but that the enzyme capacity is overwhelmed by the increased cortisol concentration 
resulting in only relatively reduced renal conversion of cortisol to cortisone.
The possible role of 11ß-HSD2 in the pathogenesis of primary hypertension
Already 35 years ago it was described that in hypertensive patients plasma cortisol levels 
and urinary excretion of cortisol are normal95, so cortisol was thought not to play a 
significant role in the pathogenesis of essential hypertension. However, while treatment 
with the synthetic glucocorticoid dexamethasone in a dose of 0.5 mg/day (suppressing 
adrenal corticosteroid production) did not change blood pressure in normotensive 
volunteers, it resulted in a fall in supine blood pressure in some patients with essential 
hypertension96. In the absence of increased circulating concentrations o f cortisol, the 
tissue effects of this hormone may be increased due to reduced 11ß-HSD2 activity. 
Therefore the potential role o f decreased activity o f 11 ß-HSD, in particular type 2, in the 
pathogenesis o f essential hypertension was investigated in several studies.
Analysis o f the corticosteroid excretion pattern in a group of 68 hypertensive patients 
provided evidence for slightly but significantly decreased activities of both 11ß-HSD2 and 
5ß-reductase compared to a control group97. In contrast, in another study in 128 patients 
with essential hypertension and 39 normotensive controls analysis o f urinary 
glucocorticoid metabolites suggested normal renal 11ß-HSD2 activity in the hypertensive 
group98. Takeda et al. studied 30 patients with low-renin essential hypertension and 20 
normotensive controls. Plasma aldosterone and urinary (THF+allo-THF)/THE ratio 
were not different between both groups99. In a study on the plasma half-life of 11a-[3H]- 
cortisol, no difference was found between 20 patients with essential hypertension and 19 
matched healthy controls. The plasma half-life o f 11a-[3H]-cortisol was prolonged in a 
subgroup of patients, suggesting decreased 11 ß-HSD activity100. However, the urinary 
(THF+allo-THF)/THE ratio was normal and no hypokalaemia or other signs of 
increased renal mineralocorticoid receptor activation were found. These studies seem to 
indicate that renal activity o f 11ß-HSD2 is normal in patients with essential hypertension. 
The combination of prolonged plasma half-life o f 11a-[3H]-cortisol and normal
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corticosteroid excretion pattern suggests that the decreased 11 ß-HSD activity in the 
subgroup of patients with essential hypertension might be located outside o f the kidney.
In the last few years, several studies have addressed the relation between renal 11 ß-HSD 
activity and salt intake. High intake of sodium results in an increase o f blood pressure, but 
the effect o f increased salt intake on blood pressure varies between individuals101. In Dahl 
salt-sensitive rats on high salt diet, renal 11ß-HSD2 mRNA levels and activity were 
significantly decreased as compared to salt-resistant controls102. This difference was not 
found when the salt-sensitive rats received a low-salt diet. In young normotensive male 
volunteers, Lovati et al.103 found that renal 11ß-HSD2 activity in the salt-sensitive group 
(defined by a difference of more than 3 mm Hg in mean arterial blood presure between 
high and low-salt diet) was significantly impaired as compared to the activity in the salt- 
resistant controls. Further studies are required to establish whether renal 11ß-HSD2 
activity may be decreased in a subgroup of salt-sensitive patients with primary 
hypertension.
Other studies focused on 11 ß-HSD activity in the skin. In a study in healthy volunteers, 
the skin vasoconstrictor sensitivity to glucocorticosteroids was increased following oral 
administration of GA, probably mediated by inhibition o f vascular 11 ß-HSD activity in 
the skin104. In a group of hypertensive patients, skin dermal vasoconstriction to topical 
glucocorticoids was increased and mean half-life o f 11a-[3H]-cortisol was prolonged as 
compared to a group of healthy volunteers. However the increased skin vasoconstrictor 
response to glucocorticoids in the hypertensive patients was not significantly correlated to 
the increased half-life of 11a-[3H]-cortisol and was also present on beclomethasone, a 
glucocorticoid that is not metabolized by 11 ß-HSD105.
Corticosteroids have been reported to potentiate vascular responses to 
catecholamines106;107. In volunteers, 7 days oral administration of carbenoxolone, an 
inhibitor of 11 ß-HSD type 1 and 2, potentiated vascular reactivity to noradrenaline (NA). 
Both forearm vasoconstriction to intra-arterial NA and the pressor response to systemic 
NA were enhanced108. Studies on licorice-induced hypertension in rats have suggested 
alternative mechanisms for effects o f GA on blood pressure and vascular tone. In this 
model for hypertension caused by inhibition of 11 ß-HSD activity, activation of the
13
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vascular endothelin 1 (ET1) system and decreased vascular NO release on acetylcholine 
were found, and both effects could be prevented by administration of spironolactone or 
eplerenone109. The effect o f inhibition of 11 ß-HSD without or with mineralocorticoid 
receptor blockers on vascular reactivity has not been studied in patients with essential 
hypertension. Also no studies have been performed to compare the in vivo vascular activity 
o f 11 ß-HSD in hypertensive patients with that in healthy volunteers.
As mentioned before, both 11 ß-HSD activity and MRs have been found in the brain. In 
rats intracerebroventricular (icv) infusion of aldosterone for 14 days resulted in elevation 
of systolic blood pressure, while no pressor effect was found when the same dose of 
aldosterone was infused subcutaneously110. A similar effect o f aldosterone was found in 
both salt-replete and salt-depleted dogs111. Administration of carbenoxolone, both orally 
and icv, and oral GA also increased blood pressure. This could completely be prevented 
by RU28318 icv51. This indicates that mineralocorticoid receptors in the central nervous 
system may participate in the pathogenesis of mineralocorticoid hypertension. A 
pathogenetic role o f cerebral 11ß-HSD2 remains to be established.
Some studies focused on the relation between 11ß-HSD2 activity in the placenta and 
primary hypertension. As already mentioned, 11 ß-HSD2 activity in the placenta regulates 
fetal exposure to maternal glucocorticoids. Increased fetal exposure to glucocorticoids 
inhibits fetal growth in rats and humans112. In epidemiologic studies an inverse relation 
between birth weight and adult blood pressure was found112;114. Thus it was hypothesized 
that decreased placental 11 ß-HSD2 activity results in increased fetal exposure to maternal 
glucocorticoids, low birth weight and subsequent hypertension at adult age115. Indeed in 
both rats and humans a positive correlation between placental 11ß-HSD2 activity and 
fetal weight was found116. Administration of dexamethasone (which is not metabolised by 
11ß-HSD2 and passess the placenta) to pregnant rats resulted in 20% reduction in birth 
weight and significantly increased systolic blood pressure in offspring, while blood 
pressure o f the mothers was not changed117. Further, administration of carbenoxolone to 
pregnant rats also reduced birth weight and elevated blood pressure in offspring118. Thus, 
based on these studies it was hypothesised that decreased placental 11ß-HSD2 activity 
may result in glucocorticoid-mediated reduction in birth weight and in an increased risk of
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hypertension at adult age. A recently published study in humans, performed in a 
population where a large intake of licorice is common in young women, did not find any 
support for this hypothesis. In this study in 1049 Finnish mothers no relation between 
intake of GA and foetal birth weight was found119.
Several studies have used HSD11B2 microsatellite markers to assess whether mutations in 
the gene coding for 11 ß-HSD2 play a role in the pathogenesis of primary hypertension. In 
a study in black subjects an association was found between D16S496 (a microsatellite 
marker flanking HSD11B2) and essential hypertension120. In contrast, in another study in 
162 French hypertensive sibships no significant relation between the HSD11B2 
microsatellite marker and hypertension was found121. These results suggest that mutations 
in the gene for 11 ß-HSD2 may only play a role in the pathogenesis o f hypertension in 
selective subgroups of patients with primary hypertension.
In conclusion, activity o f 11ß-HSD2 is crucial for prevention of renal mineralocorticoid 
activity o f cortisol. Absent or decreased renal 11ß-HSD2 activity results in 
mineralocorticoid hypertension both in AME syndrome type 1 and during excessive 
consumption of licorice. The isozyme probably does not play a role in glucocorticoid 
hypertension. In patients with essential hypertension some evidence for decreased 
systemic and skin activity o f 11 ß-HSD has been found, while renal activity seems normal. 
More recent studies suggest a relation between salt sensitivity, salt intake and renal 11 ß- 
HSD2 activity. In vascular myocytes inhibition of the enzyme results in increased vascular 
response to catecholamines, but this has not been studied in patients with essential 
hypertension. MRs in the central nervous system may participate in the pathogenesis of 
mineralocorticoid hypertension, but a role o f cerebral 11ß-HSD2 is unknown. Finally in 
the placenta 11ß-HSD2 does not protect mineralocorticoid receptors but reduces fetal 
exposure to maternal glucocorticoids. Decreased isozyme activity may result in low birth 
weight and high blood pressure at adult age.
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Outline of dissertation
As indicated before, several studies suggested that activity of 11 ß-HSD is decreased in 
hypertensive subjects as compared to normotensive subjects. The presence of both 11 ß- 
HSD1 and 11ß-HSD2 has been demonstrated in vascular tissue in in vitro studies. This 
suggests that there might be local cortisol-cortisone shuttling in vascular tissue. However, 
the physiological role of activity of the 11 ß-HSD isozymes in the vascular wall is 
unknown. It is also not known whether the local activity o f these isozymes in the 
vasculature is decreased in hypertensive patients as compared to normotensive controls.
We hypothesized that vascular activity o f the 11 ß-HSD isozymes is decreased in patients 
with primary hypertension. Consequently, these patients might be more sensitive to the 
vascular effects o f cortisol infusion. In addition, we hypothesized that decreased 11 ß- 
HSD2 activity might result in increased sensitivity to the inhibitory effect o f glycyrrhetinic 
acid (GA) on 11ß-HSD2 activity.
In the studies described in this thesis we investigated the direct effects o f cortisol before 
and after inhibition of 11 ß-HSD activity on vascular resistance. GA was used as a tool to 
inhibit local 11 ß-HSD activities. As GA was an important tool for inhibition of 11 ß- 
HSD2 activity in our studies, it was essential to have a good method for measuring plasma 
concentrations o f GA. We developed a new method for simple and reliable determination 
of the concentration of 18ß-GA in serum or plasma (chapter 2).
In chapter 3 we report the effect o f GA on forearm vascular resistance in normotensive 
and hypertensive subjects. We also studied the effect o f infusion of cortisol on renal and 
forearm vascular resistance. This was done both without and with inhibition of 11 ß-HSD 
activity. The forearm studies were done in both normotensive volunteers and patients 
with primary hypertension (chapter 4). The renal studies were carried out in patients with 
primary hypertension (chapter 5).
In addition, local vascular 11 ß-HSD activity was assessed by measuring the changes in 
arterial to venous plasma concentrations o f cortisol and cortisone across the forearm 
(chapters 3 and 4) and across the kidney (chapter 5). This was done both at baseline and 
during intra-arterial cortisol infusion.
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It is important to realize that in these studies we did not measure directly the activities of 
the 11 ß-HSD isozymes in kidney or forearm. As outlined before, arterial and venous 
plasma concentrations o f cortisol and cortisone were measured, and arterial and venous 
cortisol/cortisone ratios were calculated. Inferences o f local 11 ß-HSD activities were 
based on arterial to venous changes in concentrations o f cortisol and cortisone, and in 
cortisol/cortisone ratios. In this concept we assume that there are no other enzymes 
that locally produce or metabolise cortisol and cortisone (see figure 3). In panel a the 
baseline situation is shown in which there is no activity o f either 11ß-HSD1 or 11ß-HSD2 
in the organ involved. In this situation there is no difference between arterial and venous 
plasma concentrations of cortisol and cortisone, or between the arterial and venous
Fig. 3
organ
a F E
s* ———^2 \ E F/E
artery E- ->E vein
b F >  E
E- ->E i  t  i
The theoretical effects o f interconversion of cortisol and cortisone by the 11 ß-HSD 
isozymes in an organ on arterio-venous differences in cortisol (F), cortisol (E) and 
the cortisol/cortisone ratio (F/E). The top panel (a) shows the situation without 
cortisol-cortisone interconversion. The middle panel (b) shows the result o f 11 ß- 
dehydrogenase activity (11 ß-HSD 2). The lower panel (c) shows the result o f 11 ß- 
reductase (11ß-HSD1) activity.
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cortisol/cortisone ratios. In panel b the effect o f predominant 11 ß-HSD2 activity in an 
organ, e.g. in the kidney, is shown. In this situation cortisol would be converted to 
cortisone, resulting in a decrease o f cortisol and an increase o f cortisone across the organ. 
This would result in a decrease o f the cortisol/cortisone ratio across the organ. In panel c 
the opposite situation is demonstrated in which there would be predominant activity of 
11ß-HSD1 in an organ, e.g. in the liver. In this situation cortisone would be converted to 
cortisol. This would result in an increase of cortisol and a decrease of cortisone across 
the organ. In this situation the cortisol/cortisone ratio would increase across the organ.
In vivo, the situation is more complex. First, the arterial supply of cortisol and cortisone is 
not steady because the adrenals secrete cortisol in a circadian rhythm, with a peak in early 
morning and a nadir at midnight. Secondly, in some tissues activity o f both 11ß-HSD1 
and 11ß-HSD2 may be present at the same time. If  in vascular tissue, activity o f 11 ß- 
HSD2 were to dominate, a situation similar to that depicted in b might occur. There may 
also be predominant activity of 11ß-HSD1, resulting in a situation similar to that depicted 
in panel c. Finally, it is possible that at baseline the activity o f both isozymes is balanced. 
In this situation there would be no net arterio-venous change in cortisol, cortisone, or the 
cortisol/cortisone ratio across that tissue. However, if it would be possible to inhibit the 
activity of for instance only 11ß-HSD2, resulting in predominance of 11ß-HSD1 activity, 
then a situation similar to panel c might occur. This then would not only suggest local 
activity of 11ß-HSD1, but by implication also suggest local activity o f 11ß-HSD2. To 
study this possibility we measured the arterio-venous plasma changes in cortisol and 
cortisone concentration across the forearm both at baseline and during inhibition of 11 ß- 
HSD2 activity.
Studies in 11ß-HSD2 knock-out mice have demonstrated that decreased activity of this 
isozyme results in increased vascular sensitivity to noradrenaline and decreased action of 
the endothelium-derived nitric oxide system. Similar effects have also been described 
following administration o f glucocorticoids. This suggests that decreased activity o f 11 ß- 
HSD2 may result in increased glucocorticoid effects on blood vessels. We therefore 
investigated the effect o f inhibition of 11 ß-HSD activity on forearm vascular reactivity in 
normotensive volunteers (chapter 6).
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Abstract
A new method is described for the solid-phase extraction of 18ß-glycyrrhetinic acid from 
plasma or serum, with subsequent analysis by HPLC. New aspects o f the method include 
the use of commercially available 18a-glycyrrhetinic acid as the internal standard and the 
use o f a Bond Elut C2 (ethyl) extraction column, to avoid the need to use large volumes 
o f organic solvent to elute the isolates from the columns. Separation was achieved on a 
Shandon Hypersil BDS C18 analytical column, with a mobile phase consisting of 
acetonitrile-0.02 M  phosphate buffer, pH 5.7 (55:45, v/v). The column effluent was 
monitored at 248 nm. Compared with previous methods, the procedure is much easier to 
carry out, whereas the sensitivity (limit o f detection, 10 ng/m l and limit of quantitation, 
50 ng/ml), the precision (0.3 - 6.2%) and the accuracy (97.2 - 101.9%) are o f the same 
order o f magnitude.
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Introduction
Intake of licorice in large doses may cause sodium retention and potassium loss, which 
are associated with hypertension. One of the main constituents o f licorice is 18ß- 
glycyrrhetinic acid, which impairs the metabolism of cortisol through inhibition of the 
activity of the isozyme 11 ß-hydroxysteroid dehydrogenase type 21;2. As a result, an 
increased stimulation of mineralocorticoid receptors by cortisol may occur. The adverse 
effects of 18ß-glycyrrhetinic acid seem to be dose-dependent, however, a wide 
interindividual variation has been reported3;4. This variability may be explained by 
differences in pharmacodynamics and/or pharmacokinetics, and it is therefore necessary 
to have a reliable method for measuring 18ß-glycyrrhetinic acid concentrations in plasma.
A number o f high-performance liquid chromatographic methods for the quantitation of 
18ß-glycyrrhetinic acid in biological fluids has been published. For the sample clean-up 
of plasma or serum, some of the methods used methanol5-7, methanol together with 
urea8, acetonitrile9, or acetonitrile together with sodium bisulfate and sodium chloride10, 
to precipitate the protein. One study used a sophisticated column switching procedure11, 
while others employed a multiple liquid-liquid extraction procedure12 or solid-phase 
extraction13;14. O f the two studies that employed solid-phase extraction, one used Bond 
Elut PH (phenyl) cartridge columns13, while the other14 used C18 Sep-Pak cartridges. 
Both of them used internal standards that are not commercially available.
Takeda et al.1  did not get a clean eluate with their solid-phase extraction procedure as 
they needed a liquid-liquid extraction step to further clean up their sample. Brown­
Thomas et al.14 needed 2 ml o f methanol to elute their isolates from the cartridge 
columns, because the isolates were undesirably strongly bound to the sorbent when C18 
columns were used in conjunction with anion-pairing reagent. They had to concentrate 
their eluate by evaporation before measurement. To avoid the above-mentioned 
difficulties, we developed a new solid-phase extraction procedure using a Bond Elut C2 
(ethyl) cartridge column. Like Abe et al12, we used the commercially available 18a- 
glycyrrhetinic acid as the internal standard. Our eluate could be measured without further 
treatment and was found to be stable for more than one week at room temperature.
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Experimental
Reagents and materials
18ß-Glycyrrhetinic acid and 18a-glycyrrhetinic acid (Fig. 1) were purchased form Sigma 
(St. Louis, MO, USA). Potassium dihydrogen phosphate, di-sodium hydrogen phosphate 
2-hydrate, citric acid monohydrate, potassium hydroxide and urea were all o f analytical 
grade (Merck, Darmstadt, Germany). A Vac Elut manifold and Bond Elut C2 (ethyl) 
columns (1 ml capacity, to which a 4-ml Bond Elut reservoir was attached using a Bond 
Elut adaptor) were manufactured by Analytichem International (Harbor City, CA, USA). 
Methanol and acetronitrile were o f HPLC grade (Merck). Human blood plasma, stored at 
-20 oC, was obtained from the local blood bank.
Standard solutions
Stock solutions o f 18ß-glycyrrhetinic acid (1 m g/10 ml), and 18a-glycyrrhetinic acid (1 
m g/10 ml) were prepared in methanol. Working standard solutions were prepared by 
diluting the stock solutions with methanol. Stock solutions of both compounds were 
stable for at least six months when stored at 4 oC.
Apparatus and chromatographic conditions
The chromatographic system consisted of a Spectra Physics (Breda, The Netherlands) 
P2000 binary gradient pump, a Hewlett-Packard (Amsterdam, The Netherlands) 5 pm 
ODS Hypersil guard column (20 x 2.1 mm I.D.), a Shandon (Applied Science Group, 
Emmen, The Netherlands) 5 pm Hypersil BDS C18 analytical column (200 x 4.6 mm
I.D.) and a Spectra Physics AS 3000 autosampler with a built-in column heater. The 
mobile phase, acetonitrile 0.02 M phosphate buffer, pH 5.7 (55:45, v/v) maintained 
under a helium sparge during use, was delivered at a flow-rate o f 1 ml/min, the resulting 
pressure being 11.5 MPa. The column effluent was monitored with a Spectra Physics 
UV1000 variable wavelength detector set at 248 nm. The signal was processed by a 
Spectra Physics SP4400 integrator. The column heater was set at 40 °C and the injection 
volume was 10 pi (30 pi at concentrations lower than 0.05 pg/ml).
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Into a test tube, 100 pl o f internal standard (2 mg/100 ml) were pipetted and evaporated 
to dryness under a gentle stream of nitrogen at room temperature. Aliquots containing 
0.5 ml o f plasma and 1.5 ml of a 50% (w/w) aqueous solution of urea were successively 
pipetted into the test tube. The tube was vortex-mixed gently for 1 s. After standing for
10 min, 2.0 ml of a 0.01 M potassium citrate buffer (pH 3.0) were added to the test tube. 
The tube was again vortex-mixed gently for 1 s. The prepared sample was now ready to 
be loaded onto a C2 solid-phase extraction column.
Extraction of 18ß-glycyrrhetinic acid and 18a-glycyrrhetinic acid from plasma was 
achieved by the use of a bonded-silica solid-phase extraction column (Bond Elut C2, 1 ml 
capcity). The column was conditioned prior to use by drawing three column volumes 
(approx. 3 ml) of methanol followed by a similar volume of 0.01 M  potassium citrate 
buffer (pH 5.0) through the column. The prepared sample was loaded onto and drawn 
through the column. The column was then washed with 10 ml o f 0.01 M  potassium 
citrate buffer (pH 5.0). The cover o f the manifold was then removed and the blunt-nose 
stainless-steel needle o f the Vac Elut cover was wiped with a tissue, to remove drops of 
washing solution. The Vac Elut rack, holding a 2-ml glass sampling tube, was placed 
under the column. 18ß-Glycyrrhetinic acid and 18a-glycyrrhetinic acid were eluted from 
the column with 1 ml o f acetonitrile-0.02 M  phosphate buffer pH 7.0 (55:45, v/v). The 
eluate collected was measured as described.
Results and discussion
Chromatography
Fig. 2 shows typical chromatograms for blank plasma and for blank plasma spiked with 
18ß-glycyrrhetinic acid and the internal standard (I.S.), 18a-glycyrrhetinic acid. The 
retention times of 18ß-glycyrrhetinic acid and 18a-glycyrrhetinic acid were 10.8 and 9.6 
min, respectively, while a peak of an endogenous substance appeared at 13.2 min.
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Fig 1. Structures of 18ß-glycyrrhetinic acid and the internal standard 18a- 
glycyrrhetinic acid.
Fig 2 Chromatograms obtained for (A) blank plasma and (B) blank plasma spiked with 
0.52 pg/m l 18ß-glycyrrhetinic acid (2) and 4.4 pg/m l 18a-glycyrrhetinic acid (1). 
Injection volume, 10 pl.
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Calibration curves
The 18ß-glycyrrhetinic acid concentration in a sample was determined by comparing 
peak-height ratios o f 18ß-glycyrrhetinic acid to I.S. with a standard curve. Whenever 
samples containing 18ß-glycyrrhetinic acid were measured, a standard curve was 
generated by adding different amounts of 18ß-glycyrrhetinic acid to blank plasma. A 
linear relationship was found between the peak height ratio o f 18ß-glycyrrhetinic acid to
I.S. (y) and the plasma 18ß-glycyrrhetinic acid concentration (x), as given by the equations 
y  = 2.1310x - 0.0028 (r = 0.9986, n = 5) for the plasma concentration range 0.052-0.515 
pg/m l (I.S. = 0.44 pg/ml) and y  = 0.1978x - 0.0080 (r = 0.9997, n = 5) for the range
0.515 - 4.12 pg/m l (I.S. = 4.4 pg/ml).
Recovery
The overall recovery obtained with the extraction procedure was determined by 
comparing the peak heights o f 18ß-glycyrrhetinic acid and 18a-glycyrrhetinic acid, 
obtained after injection of non-extracted standard solutions with peak heights obtained 
after injection of extracted plasma containing equal concentrations of both compounds. 
The absolute recovery of 18ß-glycyrrhetinic acid and 18a-glycyrrhetinic acid is complete 
and independent of the concentration (Table 1).
Sensitivity, precision and applicability
The limit o f detection (signal-to-noise ratio of two) o f the method described was 10 
ng/m l and the limit o f quantitation was 50 ng/ml. Table 2 shows the precision and 
accuracy of 18ß-glycyrrhetinic acid measurement in plasma. The results o f Abe et al.12 
and of Takeda et al.13 indicate that the sensitivity of the present method is sufficient for 
pharmacokinetic studies. Both studies showed that after oral administration of approx. 25 
mg of glycyrrhizin, the plasma concentration of 18ß-glycyrrhetinic acid was higher than 
40 ng/m l during the first 24 h.
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Table 1
Recovery of 18ß-glycyrrhetinic acid and 18a-glycyrrhetinic acid from plasma
Compound Concentration
(pg/ml)
Recovery
(%)
C.V.
(%)
18ß-Glycyrrhetinic acid 0.52 97.9 4.3
1.03 93.2 2.1
2.06 94.3 3.2
4.12 97.4 6.0
18a-Glycyrrhetinic acid 0.44 98.1 4.4
4.4 95.7 5.8
For all concentrations, n=5; C.V. coefficient of variation
Table 2
Precision and accuracy of 18ß-glycyrrhetinic acid in spiked plasma samples
Spiked
concentration
(pg/ml)
Observed
concentration
(pg/ml)
Precision 
(C.V. %)
Accuracy
(%)
0.052 0.052 3.0 100.0
0.103 0.105 6.2 101.9
0.206 0.200 6.1 97.2
0.515 0.515 2.4 100.0
1.030 1.010 2.0 98.1
2.060 2.010 0.9 97.6
4.120 4.150 0.3 100.7
For all concentrations, n=5; C.V. coefficient of variation
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Conclusion
The extraction method described here for the quantitation of 18ß-glycyrrhetinic acid in 
plasma or serum is a significant improvement over previously published solid-phase 
extraction methods in terms of simplicity and general applicability. It should prove to be 
valuable for clinical monitoring of plasma or serum levels and detailed pharmacokinetic 
studies.
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GA and forearm 11 ß-HSD activities
Abstract
The 11 ß-hydroxysteroid dehydrogenase (11 ß-HSD) isozymes catalyze the interconversion 
of cortisol and cortisone. Type 1 11 ß-HSD mainly converts cortisone to active cortisol. 
Type 2 11 ß-HSD inactivates cortisol in mineralocorticoid target tissues, and its activity can 
be inhibited by glycyrrhetinic acid (GA). Inactivation of cortisol to cortisone is impaired in 
a subgroup of patients with primary hypertension. To study where this defect is located, 
we measured cortisol and cortisone concentrations in arterial plasma, in saliva and across 
the forearm at baseline and after administration of GA in normotensive and hypertensive 
subjects. GA (500 mg) or placebo was administered orally to 20 normotensive subjects in a 
placebo-controlled double-blind fashion. Further, we compared the effect of GA in 20 
patients with primary hypertension with that in 20 normotensive subjects. Cortisol and 
cortisone were measured in plasma from the brachial artery and vein and in saliva. Samples 
were obtained at 0, 90 and 150 minutes. Forearm blood flow (FBF) was measured 
simultaneously. Forearm production of corticosteroid hormones was assessed by 
multiplying the arteriovenous difference in corticosteroid concentration by FBF. The 
cortisol/cortisone ratios in arterial plasma remained at baseline level after placebo (4.9 ± 
1.2; mean ± SD), while after GA the ratios increased similarly in both normotensive 
subjects (12.3 ± 3.4) and hypertensive patients (12.2 ± 3.7). A similar effect o f GA on 
salivary cortisol/cortisone ratio was found. In both normotensive subjects and 
hypertensive patients no forearm production of cortisol or cortisone could be 
demonstrated either at baseline or after administration of GA. Thus, both before and after 
GA administration, we did not find any difference in systemic and salivary 11 ß-HSD type 2 
activity between subjects with primary hypertension and normotensive controls. Further, 
both at baseline and after GA administration we were not able to demonstrate net 
inactivation or re-activation of cortisol and cortisone by the 11 ß-HSD isozymes in the 
forearm in either normotensive or primary hypertensive subjects.
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Introduction
The 11 ß-hydroxysteroid dehydrogenase (11 ß-HSD) isozymes catalyze the interconversion 
of cortisol and cortisone. Type 1 11 ß-HSD (11ß-HSD1) is a low affinity enzyme that 
predominantly acts as a reductase, converting cortisone to the active hormone cortisol1. 
This isozyme is present in many tissues, with the highest activity in the liver2, where it 
regenerates active glucocorticoids, thereby ensuring adequate local exposure of 
glucocorticoid receptors to their endogenous ligand3. In contrast, the high affinity type 2 
11 ß-HSD isozyme (11ß-HSD2) acts only as a dehydrogenase inactivating cortisol to 
cortisone in mineralocorticoid target tissues such as kidney and salivary glands4-7. The 
activity of 11ß-HSD2 prevents inappropriate access of cortisol to mineralocorticoid 
receptors, and is essential for preserving the monopoly of aldosterone for mineralocorticoid 
receptor stimulation8;9. A congenital deficiency of 11ß-HSD2, the Apparent 
Mineralocorticoid Excess syndrome, results in severe hypertension and hypokalaemia10. The 
activity of 11ß-HSD2, but not 11ß-HSD1, can be inhibited by glycyrrhetinic acid (GA), a 
constituent of licorice11. Administration of GA results in increased ratios of cortisol to 
cortisone in plasma12 and of cortisol metabolites to cortisone metabolites in urine13.
The activities o f 11ß-HSDs thus oppose each other: 11ß-HSD1 regenerates cortisol, 
while 11ß-HSD2 inactivates cortisol. In some tissues one of the isozymes is highly 
dominant. Venous effluent from liver, for example, has a high cortisol/cortisone ratio 
reflecting mainly 11ß-HSD1 activity in this organ. Cortisol/cortisone ratio is low in blood 
from renal veins14 and in saliva15, reflecting predominant activity of 11ß-HSD2. At other 
sites activities o f both isozymes are more balanced resulting in local 'shuttling' between 
active and inactive steroids. The venous cortisol/cortisone ratio in such sites may only 
differ from the arterial ratio if activity of one of the isozymes is higher than that o f the 
other. Sites where both isozymes are expressed include the blood vessel wall16-18. 
Receptors for both mineralocorticoids and glucocorticoids have been found in rabbit 
aorta cytosol19. Furthermore, specific binding of aldosterone (a mineralocorticoid) and of 
dexamethasone (a synthetic glucocorticoid) has been demonstrated in cultured human 
arterial smooth muscle cells20. In more detailed immunohistochemical studies on rabbit
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aorta and pulmonary artery, mineralocorticoid receptors were found in both endothelial 
cells and vascular smooth muscle cells21.
It has been shown that the plasma half-life of 11a-[3H]-cortisol is increased in a subgroup 
of patients with primary hypertension22, compatible with decreased activity o f 11ß-HSD2 
in this subgroup. Interestingly, the urinary ratio of free cortisol to free cortisone, an 
indicator of renal 11ß-HSD2 activity, was not increased in this subgroup of patients with 
hypertension. In addition, plasma renin activity, which is suppressed in all syndromes 
characterized by decreased renal 11ß-HSD2 activity, was not suppressed in these patients. 
These data suggest that, in these patients with primary hypertension, the defect in 11 ß- 
HSD2 activity may be located outside the kidneys. For example, there may be an altered 
balance between type 1 and type 2 11 ß-HSD activities in peripheral blood vessels, where 
activity o f these enzymes influences cortisol-mediated changes in vascular tone16;17;23-25. 
Thus far, no studies have been performed to investigate the activities o f the 11 ß-HSD 
isozymes in the human forearm in primary hypertension.
In the present study, we assessed arterial and salivary cortisol/cortisone ratios and 
production of cortisol and cortisone across the forearm both at baseline and after 
administration of GA in healthy volunteers. In a similar design we compared forearm 
production of cortisol and cortisone in patients with primary hypertension with that in 
normotensive matched control subjects.
Methods
Subjects
Groups of 30 normotensive volunteers and 20 patients with primary hypertension 
participated in the study. All volunteers and 14 hypertensive patients were recruited by 
means of advertisement in a local newspaper. The remaining six patients were recruited 
after referral to the outpatient clinic. Apart from the increased blood pressure in the 
hypertensive patients, medical history and physical examination were normal in all 
participants. Patients with secondary hypertension and a body mass index > 30 kg/m 2 were
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excluded. Blood pressure was measured, after at least 3 weeks without anti-hypertensive 
medication or licorice consumption, with a mercury sphygmomanometer on two occasions 
(in triplicate after a 10 minute supine rest) separated by an interval o f at least 1 week. 
Hypertension was defined as a systolic blood pressure > 160 mm Hg and/or a diastolic 
blood pressure > 90 mm Hg. Normotension was defined as a systolic blood pressure 
< 140 mm Hg and a diastolic blood pressure < 85 mm Hg.
The study protocol was approved by the ethics committee of the University Medical Center 
Nijmegen. All research presented in this paper was carried out in accordance with the 
Declaration of Helsinki (1989) o f the World Medical Association. All participants gave 
written informed consent.
The subjects participated in two overlapping studies. In the first study (study I), arterial and 
salivary cortisol/cortisone ratios and forearm production of cortisol and cortisone were 
examined at baseline and after oral administration of 500 mg GA (Omnilabo, Breda, The 
Netherlands) to 10 healthy volunteers, and of placebo to 10 other healthy volunteers, in a 
randomized double-blind design. In the second study (study II), the effect of GA on 
forearm production of cortisol and cortisone and on arterial and salivary cortisol/cortisone 
ratios was assessed in 20 patients with primary hypertension. Results were compared with 
those obtained in 20 normotensive controls (including the 10 participants who received GA 
in study I). In all subjects, baseline measurements of cortisol and cortisone in plasma and 
saliva, and of forearm blood flow (FBF), were done immediately before administration of 
GA or placebo.
Protocol
The subjects were asked to abstain from licorice for at least three weeks before the study, 
and from alcohol, smoking and caffeine-containing products for at least 12 hours before the 
study. On the day preceding the experiment, 24-hour urine was collected for measurements 
of sodium, cortisol, cortisone, aldosterone and the tetrahydrometabolites o f cortisol and 
cortisone. All tests were performed with subjects in supine position, starting at 08.00 hours.
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After local anesthesia (xylocaïne, 2%), a brachial artery was cannulated with a 20-gauge 
catheter (angiocath, Becton Dickinson Inc., Sandy, UT, U.S.A.) for blood pressure 
measurement (Hewlett Packard G.m.b.H, Böblingen, Germany) and blood sampling. An 
anterograde intravenous cannula was inserted in a deep brachial vein in the same arm for 
venous blood sampling.
FBF measurements were started 30 minutes after intra-arterial cannulation. FBF was 
recorded simultaneously in both forearms by electrocardiography-triggered venous occlusion 
plethysmography using mercury-in-silastic strain gauges (Hokanson EC4, D.E. Hokanson 
Inc., Washington, D.C., U.S.A.). At 1 minute before starting FBF recordings, the hand 
circulation was occluded by inflation of wrist cuffs to suprasystolic pressure. The upper-arm 
congesting cuffs were inflated simultaneously using a rapid cuff inflator (Hokanson E-20, 
D.E. Hokanson Inc.). FBF was measured three times a minute for 4 minutes. Baseline 
samples of arterial and venous blood and saliva for measurement of cortisol and cortisone 
concentrations were taken within 2 minutes after FBF measurement. After baseline 
measurements, all participants received either 500 mg GA or placebo orally. FBF was 
measured again at 90 and 150 minutes after intake of GA or placebo, each time this was 
followed by taking samples of arterial and venous blood and of saliva for measurement of 
cortisol and cortisone concentrations. The plasma GA concentration was also measured in all 
arterial blood samples taken 150 minutes after intake of GA or placebo.
Blood and saliva sampling and laboratory measurements
Venous and arterial blood was collected in heparinized tubes. Citric acid-stimulated saliva 
samples were collected in cotton wools in plastic containers (Salivette®, Sarstedt, 
Nümbrecht, Germany). All samples for steroid measurements were stored at -20 oC until 
analyzed. The saliva samples were thawed, centrifuged (10 min at 1500 g) and the 
supernatants used for the assay.
Potassium and bicarbonate in plasma and creatinine in urine were measured using a 
Hitachi 747 analyzer (Roche Boehringer Mannheim BV, Almere, The Netherlands). Ion- 
selective electrodes were used for potassium measurements in plasma. Bicarbonate was 
measured enzymatically with phosphoenolpyruvate carboxylase and malate dehydrogenase.
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Urinary creatinine was determined colorimetrically. Sodium and potassium concentrations 
in urine were measured with a flame photometer (EFIX 5056, E. Merck Nederland BV, 
Amsterdam, The Netherlands).
Cortisol and cortisone in both plasma and saliva as well as 24-hour urinary free cortisol 
and cortisone were measured by radioimmunoassay after previous extraction with organic 
solvents and paper chromatography26;27.
Plasma and urinary aldosterone concentrations were measured after extraction and paper 
chromatography as described earlier28;29. Urinary 5ß-tetrahydrocortisol, 5ß-tetrahydro- 
cortisone and 5a-tetrahydrocortisol were measured according to Weykamp et al?1, using a 
gas chromatograph equipped with a flame ionization detector (HRGC 5300 Mega series, 
Carlo Erba Instruments Rodano (Milan), Italy) and fitted with a WCOT fused-silica 
capillary column (Chrompack, Middelburg, The Netherlands, 25 m x 0.25 mm internal 
diameter with a fill thickness o f 0.12 pm, liquid phase CP-SIL-5CB). Plasma GA 
concentration was measured using a high performance liquid chromatography method30. 
The lower limit of detection of GA was 10 ng/ml, the intra-assay coefficient o f variation 
was 6.2 % at 0.103 pg/m l and 0.3 % at 4.120 pg/ml.
Calculations
The forearm production of a corticosteroid hormone was assessed by multiplying the 
arteriovenous difference in corticosteroid concentration by FBF. The forearm production 
of a corticosteroid is expressed as pmol • min-1 • 100 ml -1 forearm tissue.
Statistics
All results are expressed as mean ± SEM unless indicated otherwise. Differences between 
groups regarding baseline values were assessed with the unpaired Student’s t-test. 
Differences in responses to GA and placebo and between normotensive and hypertensive 
study groups were analyzed with repeated-measurements ANOVA. Correlation 
coefficients were calculated using Spearman’s rank correlation. Significance was accepted 
at P < 0.05.
46
GA and forearm 11 ß-HSD activities
Table 1. Clinical characteristics and laboratory results at baseline
Parameter
Study I (normotensive subjects) 
Placebo (n=10) GA (n=10)
Study II
Normotensive Hypertensive 
subjects subjects 
(n=20t) (n=20)
Age (years) 50.2 ± 9.7 49.4 ± 10.7 43.0 ± 11.6 47.9 ± 8.1
Gender (female/male) 6 /  4 5 /  5 10 /  10 9 /  11
BMI (kg/m2) 25.6 ± 2.5 24.5 ± 3.4 24.2 ± 2.8 25.3 ± 2.5
Systolic BP (mm Hg) 132 ± 11 128 ± 10 124 ± 9 159 ±16
Diastolic BP (mm Hg) 77 ± 5 78 ± 5 76.± 7 101 ± 8
Heart rate (beats/minute) 63 ± 9 60 ± 10 60 ± 9 66 ± 11
Plasma potassium (mmol/l) 4.1 ± 0.3 4.3 ± 0.2 4.3 ± 0.4 4.2 ± 0.3
Plasma bicarbonate (mmol/l) 26.1 ± 2.8 26.6 ± 4.7 26.5 ± 3.9 26.9 ± 2.4
Urinary sodium (mmol/24 h) 139 ± 73 160 ± 53 169 ± 74 160 ± 63
Urinary potassium (mmol/24 h) 72 ± 18 84 ± 21 78 ± 21 70 ± 24
Urinary creatinine (mmol/24 h) 12.0 ± 3.9 13.4 ± 1.9 13.2 ± 4.0 13.2 ± 4.6
Urinary cortisol (nmol/24 h) 46 ± 25 92 ± 56 75 ± 45 68 ± 29
Urinary cortisone (nmol/24 h) 186 ± 96 253 ± 27 214 ± 23 187 ± 88
Urinary aldosterone (nmol/24 h) 16.3 ± 7.1 17.4 ± 12.8 16.7 ± 10.0 17.8 ± 7.3
Urinary 5ß-THF (^m ol/24 h) 5.2 ± 2.0 6.3 ± 3.3 5.4 ± 2.7 5.7 ± 2.1
Urinary 5a-TH F (^m ol/24 h) 3.5 ± 1.8 6.0 ± 5.0 5.2 ± 3.9 4.6 ± 2.8
Urinary 5 ß -THE (^m ol/24 h) 9.7 ± 3.0 13.1 ± 8.7 11.4 ± 6.9 10.3 ± 4.6
Urinary (5ß-TH F+5a-TH F)/5ß-TH E 0.91 ± 0.23 1.03 ± 0.39 0.98 ± 0.33 1.04 ± 0.26
All plasma measurements were obtained using arterial samples. Values are mean ± SD. BMI, 
body mass index; BP, blood pressure (measured using a sphygmomanometer); THF, 
tetrahydrocortisol; THE, tetrahydrocortisone; P, placebo; GA, glycyrrhetinic acid. No 
differences were found between normotensive and hypertensive groups or between the 
placebo and GA groups, except for the differences in systolic and diastolic blood pressure 
between normotensive and hypertensive subjects. 
t n= 19 for urine values
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Results
Study I: effects of administration of G A compared with placebo in normotensive subjects 
Characteristics of the participants are shown in Table 1, and FBFs in Table 2. Baseline 
clinical and laboratory parameters for the 10 volunteers who received placebo did not differ 
from the 10 volunteers who received 500 mg GA (Table 1).
Arterial measurements
The effects o f placebo and GA administration on arterial concentrations o f cortisol and 
cortisone and on the cortisol/cortisone ratio in arterial plasma are shown in Figure 1. 
After placebo, the cortisol and cortisone concentrations decreased in arterial plasma 
because of their diurnal rhythm. After GA, the diurnal decrease o f cortisol was slightly, 
but not significantly, less than after placebo, while the decrease in cortisone concentration 
over time was significantly larger after GA than after placebo. Administration of GA 
resulted in a significant increase in arterial cortisol/cortisone ratio (P < 0.001), compatible 
with the systemic inhibition of 11 ß-HSD2 activity.
Plasma GA concentrations were measured in arterial plasma samples obtained 150 
minutes after oral intake of placebo or GA. The GA concentration was below the limit of 
detection in plasma from volunteers who received placebo capsules. In the GA group the 
plasma GA concentration was 6.13 ± 2.1pg/ml (range 3.6 - 10.2 pg/ml). There was a 
significant relationship between the plasma cortisol/cortisone ratio and plasma GA 
concentration (r = 0.77, P = 0.01).
Saliva measurements
The effects of placebo and GA administration on concentrations of cortisol and cortisone 
and on the cortisol/cortisone ratio in saliva are shown in Figure 1. After placebo, the 
cortisol concentration in saliva decreased because of its diurnal rhythm. After GA this 
decrease in salivary cortisol was no longer present (P < 0.01). The decrease in salivary 
cortisone concentration after GA was not different from that after placebo. Consequently, 
administration of GA resulted in a significant increase in the salivary cortisol/cortisone ratio 
(P < 0.001), compatible with inhibition of salivary 11ß-HSD2 activity.
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Fig. 1
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Effects of oral administration of GA on the concentrations of cortisol and cortisone and on their 
ratio in arterial (left panels) and venous (middle panels) plasma and in saliva (right panels) 
compared with placebo.
GA (500 mg) was administered orally at t = 0 min. □, Subjects receiving placebo (n = 10);
■, subjects receiving GA (n = 10). Asterisks (*) denote statistically significant differences between 
groups (ANOVA for repeated measures followed by Student’s t-test).
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Forearm measurements
Neither placebo nor GA affected FBF (Table 2). At baseline, the calculated forearm 
production of cortisol was 11.2 ± 44.6 pmol • min-1 • 100 ml -1 tissue (95 % confidence 
interval 10.9 — 28.1 pmol • min-1 • 100 ml -1), and that of cortisone 7.8 ± 13.6 pmol • min-1 • 
100 ml -1 (95 % confidence interval 2.7 — 13.0 pmol • min-1 • 100 ml -1), indicating that, with 
the technique used, substantial production of neither cortisol nor cortisone could be 
demonstrated in the forearm. After administration of GA, again no production of cortisol 
or cortisone in the forearm could be demonstrated (Figure 2).
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Effects of GA on forearm production of cortisol (upper panels) and cortisone (lower panels) 
in normotensive volunteers.
GA (500 mg) was administered orally at t = 0 min. Forearm production of a steroid was 
assessed by multiplying the arteriovenous difference in corticosteroid concentration by 
FBF. The left panels show the individual data from 10 subjects in the placebo group, and 
the right panels show the individual data from 10 subjects in the GA group. No 
differences between groups were found.
Table 2. Effects of GA on FB F in norm otensive volunteers
FBF (ml ■ min-1 ■ 100 ml -1 tissue)
Time (minutes) Placebo GA
0 2.33 [1.92 -  2.75] 2.49 [1.93 -  3.04]
90 2.16 [1.57 -  2.76] 2.32 [1.68 -  2.96]
150 2.54 [1.61 -  3.49] 2.59 [1.65 -  3.53]
‘Time’ is the time after oral administration of placebo or GA (500 mg). Data are 
expressed as mean [95% confidence interval] for n = 10 in each group. There were 
no significant differences between groups, or between time points within a group.
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Study II: effects of administration of GA in hypertensive subjects compared to 
normotensive subjects
Baseline clinical and laboratory parameters for the 20 hypertensive subjects and the 
normotensive volunteers are shown in Table 1. Blood pressure was clearly increased in the 
hypertensive patients, but no differences in other clinical and laboratory parameters were 
found. In particular, plasma potassium and bicarbonate concentrations and urinary ratio of 
cortisol metabolites to cortisone metabolites did not differ between the two groups. 
Baseline FBF was significantly increased in hypertensive patients compared to 
normotensive subjects (Table 3).
Arterial measurements
Arterial concentrations o f cortisol and cortisone at baseline were not significantly 
different between normotensive and hypertensive subjects, resulting in similar 
cortisol/cortisone ratio’s at baseline (results not shown). GA administration increased the 
cortisol/cortisone ratio to similar extent in the two groups (Figure 3, upper left panel). 
The GA concentration in arterial plasma at 150 minutes was not significantly different 
between the two groups (normotensive, 5.3 ± 2.1 pg/ml; hypertensive, 5.4 ± 2.0 pg/ml). 
The correlation coefficients for the relation between arterial GA concentration and 
arterial cortisol/cortisone ratio were 0.61 and 0.72 (both P < 0.01) for hypertensive 
patients and normotensive volunteers, respectively.
Saliva measurements
Salivary cortisol and cortisone concentrations and their ratios did not differ between 
normotensive and hypertensive subjects at baseline. In both groups the cortisol/cortisone 
ratios increased significantly after GA (both P < 0.001), but no difference between 
normotensive and hypertensive subjects was detected (Figure 3, lower left panel).
Forearm measurements
GA did not affect FBF in either normotensive or hypertensive subjects (Table 3). At 
baseline, production o f neither cortisol nor cortisone was demonstrated in the forearm of 
either hypertensive or normotensive subjects (Figure 3, right panels). After administration
51
Chapter 3
Fig 3
«co
!= <0£  ra
8 a
o «
(A L-~ a> 1 1
5  *
o
o
■oo
a
oM
'■Eoo
«co
oa
Time (minutes)
Effects o f GA on the plasma and salivary cortisol/cortisone ratios and on forearm production 
o f cortisol and cortisone
Left panels: effects o f GA (500 mg orally at t  = 0 min) on the cortisol/cortisone ratios in 
arterial plasma (upper panel) and saliva (lower panel) in normotensive (o; n=20) and 
hypertensive (•; n=  20) subjects. The cortisol/cortisone ratio increased significantly in both 
groups (P < 0.001, AN O V A  for repeated measures). N o differences between groups were 
found.
Right panels: effects o f GA (500 mg orally at t  = 0 min) on forearm production o f cortisol 
(upper panel) and cortisone (lower panel) in patients with primary hypertension (•; n=20) and 
in normotensive controls (o; n=20). Forearm production o f a steroid was assessed by 
multiplying the arteriovenous difference in corticosteroid concentration by FBF. N o 
differences between groups were found.
T ab le  3 F B F  values in  no rm otensive  co m p ared  w ith  hypertensive sub jec ts
FBF (ml ■ min-1■ 100 ml -1 tissue)
Time (minutes) Normotensives Hypertensives
0 2.11 [1.73 -  2.49] 2.90 [2.30 -  3.51]*
90 1.95 [1.58 -  2.32] 2.76 [2.19 -  3.33]*
150 2.14 [1.57 -  2.71] 2.86 [2.28 -  3.44]
‘Tim e’ is the time after oral administration o f placebo or G A  (500 mg). D ata are 
expressed as m ean [95% confidence interval] for n  = 20 in each group. Significance o f 
differences: * P < 0.05 compared w ith norm otensive group. There were no significant 
differences between time points within a group.
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of GA, no local production of either cortisol or cortisone could be demonstrated in the 
forearm in either group.
Discussion
In the present study, we have explored 11 ß-HSD activities in patients with primary 
hypertension and in normotensive control subjects both before and after administration of 
GA or placebo. 11 ß-HSD activities were assessed systemically and in a classical 
mineralocorticoid target tissue by measuring cortisol/cortisone ratios in arterial plasma and 
saliva, respectively, and in the forearm by comparing arterial and venous concentrations of 
cortisol and cortisone.
In normotensive subjects the administration o f GA resulted in a significant increase of 
arterial and salivary cortisol/cortisone ratios, demonstrating inhibition of 11ß-HSD2 activity 
both systemically and in the salivary glands. A similar effect of GA on the plasma 
cortisol/cortisone ratio has been demonstrated in several other studies12;13;31.
We could not detect generation of cortisol or cortisone in the forearm at baseline in 
normotensive subjects. There are three possible explanations for this finding. First, it is 
possible that there is no activity of the 11 ß-HSD isozymes in the human forearm at all. In 
our study we used arterial and venous concentrations o f cortisol and cortisone to assess 
forearm cortisol-cortisone metabolism. In a similar approach Katz et al?2 measured cortisol 
and cortisone concentrations in serum samples from radial artery and brachial vein, and also 
found no differences between arterial and venous concentrations of cortisol and cortisone. 
In contrast, Asmal and colleagues33 infused [3H]cortisol into the brachial artery in humans 
and demonstrated local generation of [3H]cortisone in the forearm, consistent with 11 ß- 
HSD2 activity. Secondly, it is possible that at baseline there is no net difference in the 
combined effect of 11ß-HSD1 and 11ß-HSD2 activities. However, even after inhibition of
11 ß-HSD2 activity by GA we could not detect forearm generation of cortisol. This might 
be due to insufficient inhibition of forearm 11ß-HSD2 activity by GA, but, in view of the 
clear GA-mediated inhibition of 11ß-HSD2 activity in the salivary glands, this seems
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unlikely. Thirdly, it might be that activities of both isozymes are very low and that methods 
using arterio-venous differences across the forearm lack the sensitivity required to detect 
isozyme activity in the human forearm. A further limitation of such studies is that they do 
not measure activity of the 11 ß-HSD isozymes directly, but only changes in cortisol and 
cortisone concentration across the forearm. For assessment of in vivo activity of 11 ß-HSD 
isozymes more specific methods may be required, e.g. the infusion of deuterated cortisol, as 
suggested by Andrew et aß4.
In patients with hypertension, we have shown that there are no abnormalities in the basal 
cortisol/cortisone ratios in arterial plasma or saliva, and that the incremental effect of GA 
on these variables did not differ from that in normotensive subjects. This indicates that 
sensitivity to GA in our group of patients with primary hypertension did not differ from 
that in the normotensive healthy volunteers, suggesting that 11ß-HSD2 activities 
systemically and in the salivary gland, a classical mineralocorticoid target tissue, were not 
decreased in our patients with primary hypertension. We could not detect the generation of 
cortisol or cortisone in the forearm at baseline either in normotensive volunteers or in 
patients with primary hypertension. In addition, after GA administration we did not detect 
forearm production of cortisol or cortisone in either normotensive or hypertensive subjects. 
Since activity of the 11 ß-HSD isozymes in the forearm could not be demonstrated by the 
technique used, it was not possible to compare forearm 11 ß-HSD activities in hypertensive 
patients with those in normotensive subjects.
As indicated above, the role o f 11ß-HSD2 in the pathogenesis of primary hypertension is 
unclear. 11ß-HSD2 activity is decreased in a subgroup of patients with primary 
hypertension22;35. Recently, Lovati et al?6 showed an increased urinary ratio of cortisol 
metabolites to cortisone metabolites in salt-sensitive normotensive male volunteers 
compared to salt-resistant matched controls. The decreased renal activity of 11ß-HSD2 in 
the salt sensitive volunteers may result from genetic variants of the enzyme, as suggested by 
the authors36, or may be due to inhibition of 11ß-HSD2 activity by GA or GA-like factors37. 
An alternative possibility is that variants in the gene coding for 11ß-HSD2 result in 
increased sensitivity of 11ß-HSD2 for endogenous and/or exogenous inhibitory factors. In
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previous studies on renal 11ß-HSD2 activity in primary hypertension, the urinary ratio of 
cortisol metabolites to cortisone metabolites was increased in one study35, but not in three 
other studies including the present study38;39. It is possible that renal 11ß-HSD2 activity is 
only decreased in a salt-sensitive subgroup of patients with primary hypertension, so that 
differences in selection of hypertensive patients may explain the contradicting results in 
these studies.
In conclusion, we did not find a difference in cortisol/cortisone ratios in arterial plasma or 
saliva between normotensive and hypertensive subjects, either before or after administration 
of GA, suggesting that systemic and salivary 11ß-HSD2 activities are not different in 
primary hypertension compared to those in normotensive controls. Further, in the present 
study we could not demonstrate forearm production of cortisol or cortisone either at 
baseline or after administration of GA, indicating that activities of the 11 ß-HSD isozymes 
in the forearm may be balanced but very low, or not present at all. This does not exclude 
the possibility that decreased isozyme activity may play a role in subgroups of patients with 
primary hypertension. Further studies on the role of 11ß-HSD2 in the pathogenesis of 
primary hypertension may require more specific techniques, and/or could focus on 
differences between salt-resistant and salt-sensitive subgroups.
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Forearm cortisol infusion and 11 ß-HSDs
Abstract
Background Vascular tone is increased in primary hypertension, and glucocorticoids 
affect vascular tone. Local cortisol availability is modulated by activity of 11 ß- 
hydroxysteroid dehydrogenase (11 ß-HSD). Since this activity may be decreased in patients 
with primary hypertension, vascular sensitivity to cortisol may be increased in these 
patients. We studied the acute effect of cortisol on forearm vascular resistance (FVR) by 
infusing cortisol directly in the brachial artery, both without and with inhibition of 11ß- 
HSD, in normotensive and hypertensive subjects.
Design Twenty normotensive volunteers and 20 patients with primary hypertension 
participated in the study. After a 10 minutes infusion of vehicle (glucose 5%), cortisol was 
infused in the brachial artery in three stepwise increasing doses (3.5, 10.5 and 35 pg per 100 
ml forearm volume), each for 10 minutes. Next, participants received placebo or 500 mg 
glycyrrhetinic acid (GA) orally, and 150 minutes later the same infusion schedule was 
repeated. FVR was measured during the last 5 minutes of the infusion of vehicle and each 
dose. Arterial and forearm venous plasma samples for measurement of cortisol and 
cortisone were taken at the end of the infusions of glucose 5% and the highest cortisol 
dose.
Results In both normotensive and hypertensive subjects, neither infusion of cortisol nor 
administration of GA changed FVR. Also two hours after cortisol-infusion there still was 
still no change in FVR in both the normotensive and hypertensive groups who received 
placebo. Following infusion of the highest cortisol dose, total plasma cortisone levels in 
venous plasma were decreased compared to levels in arterial plasma (36 ± 3 and 49 ± 4 
nm ol/l, respectively, P<0.05). The protein bound venous cortisone was 37.1 ± 4.8 nm ol/l 
during vehicle compared to 23.9 ± 3.7 nm ol/l during cortisol infusion (P<0.01), whereas 
the free cortisone level was not altered by cortisol infusion.
Conclusions In both normotensive and hypertensive subjects, high dose cortisol­
infusion both without and with 11 ß-HSD inhibition did not change FVR either 
immediately or after two hours. We could not demonstrate in vivo 11ß-HSD activity in 
forearm vascular tissues. When binding of cortisone to corticosteroid-binding globulin is 
changed, e.g. during cortisol-infusion, arterio-venous changes in cortisone can not reliably 
be used to assess (alterations in) local 11 ß-HSD activity.
61
Chapter 4
Introduction
Hypertension is a well-recognised complication of cortisol excess. It is found in about 
80% of patients with Cushing’s syndrome1. In healthy normotensive subjects oral cortisol 
administration results in an increase of blood pressure2. In addition, there is some 
evidence that cortisol may play a role in the pathogenesis of primary hypertension3;4.
The mechanism by which cortisol excess results in an increase of blood pressure is not 
known. The activity of the sympathetic nervous system, which is important in short-term 
regulation of blood pressure, is not increased by cortisol5. Administration of 
glucocorticoids and mineralocorticoids enhances vasoconstriction to noradrenaline and 
cold stress6;7. In addition, cortisol administration results in decreased NO-dependent 
vasodilation8. It is possible that the latter effects are mediated by binding of cortisol to 
classic corticosteroid receptors in vascular tissue. The presence of glucocorticoid 
receptors has been demonstrated in cultured arterial smooth muscle cells9. 
Mineralocorticoid receptors have been found in both endothelial cells and vascular 
smooth muscle cells derived from pulmonary artery10.
In vivo, activity of 11 ß-hydroxysteroid dehydrogenase type 2 (11ß-HSD2) prevents specific 
binding of cortisol to mineralocorticoid receptors. This isozyme converts cortisol to 
inactive cortisone, thus protecting mineralocorticoid receptors from stimulation by 
cortisol11. The activity of 11 ß-HSD can be inhibited by glycyrrhetinic acid (GA), resulting 
in an increase of the cortisol/cortisone ratio in plasma12. In contrast, 11 ß-HSD type 1 
(11ß-HSD1) regenerates cortisol, thus ensuring adequate local exposure of glucocorticoid 
receptors to cortisol13;14. Both 11ß-HSD1 and 11ß-HSD2 are expressed in the blood 
vessel wall15;16. Decreased activity of 11ß-HSD2, e.g. in transgenic knock-out mice17 or by 
pharmacological inhibition4, induces endothelial dysfunction and enhanced 
vasoconstriction to noradrenaline. In previous studies in humans using the difference in 
cortisol/cortisone ratio across the forearm to assess vascular 11 ß-HSD activity, no 
evidence for 11 ß-HSD activity in the forearm blood vessels could be demonstrated18. 
However, in vascular tissue there may be a balance between the activities of both 11 ß-
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HSD isozymes resulting in no net change in plasma concentrations of either cortisol or 
cortisone across the forearm.
In addition to the effects of cortisol that are mediated via classic corticosteroid receptors, 
steroid effects may also be mediated through non-classical, nongenomic pathways. 
Recently it was demonstrated that administration of cortisol resulted in rapid intracellular 
effects in human uterine and chorionic arteries19. Importantly, these rapid effects of 
cortisol were only present during inhibition of 11 ß-HSD activity.
Little is known about direct effects of cortisol on forearm vascular resistance in humans in 
vivo. In one study in healthy subjects, infusion of cortisol (as hydrocortisone-21-succinate) 
directly into the brachial artery did not change forearm vascular resistance, even during 
inhibition of 11ß-HSD activity20. However, hydrocortisone-21-succinate is an ester that 
needs to be hydrolyzed before cortisol becomes available, a process that may take several 
hours. Therefore it remains possible that intra-arterial administration of cortisol itself may 
directly affect forearm vascular tone, especially when 11 ß-HSD activity is inhibited or 
decreased.
In the present study we investigated whether exposure of forearm arterial blood vessels to 
high cortisol concentrations, either without or with inhibition of 11 ß-HSD activity, would 
acutely alter forearm vascular resistance. 11ß-HSD2 activity may be decreased in patients 
with primary hypertension4;21, and this group exhibited increased in vivo constrictor 
sensitivity to glucocorticoids in subcutaneous dermal vessels22. We hypothesized that 
these patients are more sensitive to cortisol and would show a smaller incremental 
inhibitory effect of GA on 11 ß-HSD activity. Therefore, the studies were performed in 
both normotensive and hypertensive subjects. We also measured the effect of cortisol 
infusion on the change in plasma cortisone across the forearm in search for local 11 ß- 
HSD2 activity in the forearm.
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Subjects and methods
Subjects
Twenty normotensive volunteers and 20 patients with primary hypertension participated in 
the study. All participants were recruited by means of advertisement in a local newspaper. 
Medical history and physical examination were normal in all participants except for the 
increased blood pressure in the hypertensive patients. Patients with secondary hypertension 
or a body mass index >30 kg/ m2 were excluded. Blood pressure was measured after at least 
3 weeks without antihypertensive medication with a mercury sphygmomanometer on two 
occasions (in triplicate after 10 minutes supine rest) with an interval of at least one week. 
Hypertension was defined as a systolic blood pressure over 160 mm Hg and/or a diastolic 
blood pressure over 90 mm Hg. Normotension was defined as a systolic blood pressure 
under 140 mm Hg and a diastolic blood pressure under 85 mm Hg. The study protocol was 
approved by the ethics committee of the University Medical Center Nijmegen. All 
participants gave written informed consent.
Protocol
All subjects were asked to abstain from licorice for at least three weeks before the study, 
and from alcohol, smoking and caffeine-containing products for at least 12 hours before the 
study. On the day preceding the experiment, 24-hour urine was collected for measurements 
of sodium, potassium, aldosterone and the tetrahydrometabolites of cortisol and cortisone.
All tests were performed with subjects in supine position, starting at 8.00 a.m. After local 
anesthesia (xylocaïne, 2%), a brachial artery was cannulated with a 20-gauge catheter 
(angiocath, Becton Dickinson Inc., Sandy UT, USA) for blood pressure measurement 
(Hewlett Packard GmbH, Böblingen, Germany), infusion of cortisol and blood sampling. 
An anterograde cannula was inserted in a deep brachial vein in the same arm for venous 
blood sampling.
Forearm blood flow (FBF) measurements started 30 minutes after intra-arterial cannulation. 
FBF was recorded simultaneously in both forearms by electrocardiography-triggered 
venous occlusion plethysmography using mercury-in-silastic strain gauges (Hokanson EC4, 
D.E. Hokanson Inc., Washington D.C., USA). One minute before starting FBF recordings 
the hand circulation was occluded by inflation of wrist cuffs to suprasystolic pressure. The
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upper arm congesting cuffs were inflated simultaneously using a rapid cuff inflator 
(Hokanson E-20, D.E. Hokanson Inc., Washington D.C., USA). FBF was measured three 
times a minute for four minutes. During every FBF measurement blood pressure and heart 
frequency were measured simultaneously. Forearm vascular resistance (FVR) was calculated 
by dividing FBF by mean arterial blood pressure (MAP) and expressed in arbitrary units 
(AU). To correct for eventual systemic effects, alterations in vascular tone were also 
analysed by calculating FVR ratios (FVR infused arm /  FVR non-infused arm).
After the first FBF measurement, arterial and venous blood samples were collected for 
measurement of plasma cortisol and cortisone concentrations at baseline. Next, infusion of 
vehicle in the brachial artery was started and followed by infusion of cortisol. Cortisol was 
dissolved in ethanol (final concentration 0.7% ethanol in 5% glucose, for vehicle and all 
cortisol infusions) and infused in three increasing doses of 3.5, 10.5 and 35 pg per 100 ml 
forearm volume, respectively. Each dose was infused over a period of 10 minutes. FBF was 
measured during the last four minutes of every infusion. After measurement of the last FBF 
again arterial and venous blood samples were taken.
To exclude a possible effect of ethanol 0.7% on FVR, we first performed a pilot study in 4 
normotensive volunteers. Infusion of solutions containing ethanol 0.7% without cortisol, 
following exactly the same infusion, did not alter FBF, FVR, or blood pressure (results not 
shown).
Next, all participants received either 500 mg glycyrrhetinic acid (GA) (Omnilabo, Breda, 
The Netherlands) or placebo orally in a randomized double-blind design. Two hours after 
administration of GA or placebo the same protocol consisting of FBF measurements, 
cortisol infusion, and collection of arterial and venous blood samples was repeated.
Blood sampling and laboratory measurements
Venous and arterial blood was collected in heparinized tubes. All samples for steroid 
measurements were stored at -20 oC until analyzed. Urinary creatinine was determined 
colorimetrically. Sodium and potassium concentrations in urine were measured with a 
flame photometer (EFIX 5056, E. Merck Nederland BV, Amsterdam, The Netherlands).
Cortisol and cortisone in plasma were measured by radioimmunoassay after previous 
extraction with organic solvents and paper chromatography23;24. These measurements
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were only done in normotensive participants. Urinary aldosterone concentrations were 
measured after extraction and paper chromatography as described earlier25;26. Urinary 5ß- 
tetrahydrocortisol (5ß-THF), 5ß-tetrahydrocortisone (5ß-THE) and 5a-tetrahydrocortisol 
(5a-THF) were measured according to Weykamp et a/.24, using a gas chromatograph 
equipped with a flame ionization detector (Carlo Erba Instruments HRGC 5300 Mega 
series Rodano (Milan), Italy) and fitted with a WCOT fused-silica capillary column 
(Chrompack, Middelburg, The Netherlands, 25 m x 0.25 mm i.d. with a film thickness of 
0.12 pm, liquid phase CP-SIL-5CB).
The free plasma concentrations of cortisol and cortisone were determined as described 
before27: 0.8 ml of plasma was dialyzed against 0.8 ml buffer (phosphate 0.05 m ol/l, NaCl 
0.1 m ol/l, pH  7.40) for 3 hours in a Diachema dialysis apparatus. The concentrations of 
the steroid hormones were measured in the dialysate using the same procedure as 
described for total plasma cortisol and cortisone. The free fractions fo’ and the free 
hormone concentrations Fo ’ were estimated for undiluted plasma using a formula that 
takes into account the 1:1 dilution implicit in equilibrium dialysis:
fo ’ = 1 /  (Ho /  F  -  V f /  Vo + 1)
Fo’ = Ho x Fo
where H o = total hormone concentration (nmol/l); F = (free) hormone concentration as 
measured in dialysate, and Vf /  Vo = ratio of total volume of dialysis system to sample 
volume, which for the present case equals 2.
Statistical analysis
All data are presented as mean ± SEM unless indicated otherwise. Comparisons within 
groups were analysed by Wilcoxon signed-ranks test. Comparisons between 2 different 
groups were analysed by Mann-Whitney U test. FVR results were analysed by ANOVA 
for repeated measures. P values < 0.05 were considered statistically significant. The study 
design allowed for a power of 80% to detect a 50% difference in FVR.
66
Forearm cortisol infusion and 11 ß-HSDs
Results
Baseline characteristics
The clinical characteristics at baseline are presented in table 1. In both the normotensive 
and the hypertensive group there was no difference in the ratio of tetrahydrometabolites 
of cortisol over the tetrahydrometabolite of cortisone between placebo- and GA-group, 
suggesting that at baseline there is no difference in overall 11 ß-HSD activity between 
placebo- and GA-groups. There was no difference between the hypertensive placebo- and 
GA-group, except for the urinary potassium excretion per 24 hours that was significantly 
lower in the hypertensive GA-group than in the placebo-group. There were no differences 
in baseline characteristics between the normotensive groups and hypertensive groups.
Forearm hemodynamics during repeated intra-arterial infusion of cortisol without and with 11 ß-H SD  
inhibition
In the normotensive placebo-group, the intra-arterial infusion of cortisol did not alter 
FVR either during the first or during the second cortisol infusion (fig 1), and there was no 
significant difference in the course of the FVR between the first and the second cortisol 
infusion. In the normotensive GA-group, there was neither a significant difference in 
FVR during vehicle before and after GA, nor during cortisol infusion before and after 
GA. During the second cortisol infusion, there was no significant difference in the course 
of the FVR between placebo-group and GA-group.
In the hypertensive placebo-group, the intra-arterial infusion of cortisol did not alter FVR 
either during the first or during the second cortisol infusion (fig 1). There was no 
significant difference in the course of the FVR between the first and the second cortisol 
infusion. In the hypertensive GA-group, there was neither a significant difference in FVR 
during vehicle before and after GA, nor during cortisol infusion before and after GA. 
During the second cortisol infusion, there was no significant difference in the course of 
the FVR between hypertensive placebo-group and GA-group.
Cortisol-infusion did not alter the FVR ratio in any group. In the normotensive placebo­
group the FVR ratios during the first and second vehicle infusion were 0.85 ± 0.08 and 
0.96 ± 0.13, demonstrating no significant effect on FVR even 2 hours after the 
first cortisol infusion. Similarly, cortisol infusion did not alter FVR ratio’s in the other
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Table 1. Clinical characteristics and laboratory results at baseline
Variable N orm otensive  subjects H ypertensive subjects
P lacebo-group G lycyrrhetinic acid P lacebo-group G lycyrrhetinic acid
(n=10) group  (n=10) (n=10) group  (n=10)
M ean arterial b lood  pressure (m m  Hg) 96 + 13 90 ± 8 114 ± 4 111 ± 4
Age (years) 51 ±  12 53 ± 7 49 ±  10 55 ± 9
Sex (m ale/fem ale) 3 / 7 5 / 5 6 / 4 7 / 3
B M I (k g /m 2) 25 ± 3 24 ± 4 26 ± 2 25 ± 3
D ura tion  hypertension  (years) 11 ±  12 12 ±  10
Sm oker (yes/no) 1 /  9 1 /  9 2 / 8 4 / 6
P otassium  (m m ol/l) 4.1 ±  0.1 4.2 ±  0.2 4.1 ± 0 .2 4.1 ±  0.2
B icarbonate (m m ol/l) 27 ± 2 26 ± 2 25 ± 2 27 ± 2
Creatinine ().imol/l) 83 ±  10 82 ± 8 83 ± 8 76 ± 2 1
U rinary aldosterone (n m o l/2 4  h) 23 ±  12 21 ±  12 26 ±  11 20 ± 9
U rinary creatinine (m m ol/2 4  h) 13 ± 3 11 ±  3 13 ± 3 12 ±3
U rinary sodium  (m m o l/2 4  h) 138 ±  47 158 ± 7 0 178 ±  72 148 ±  72
Urinary potassium  (m m o l/2 4  h  ) 83 ±  10 77 ± 19 97 ± 2 1 73 ±  26a
T etrahydrocortiso l (p m o l/24 h) 6.8 ±  3.0 4.0 ±  1.0 6.1 ± 3 .2 5.5 ±  2.6
A llo-tetrahydrocortiso l ().im ol/24 h) 6.9 ±  3.7 4.9 ± 2.3a 4.8 ± 3 .7 5.6 ±  4.0
T etrahydrocortisone (p m o l/24 h) 11.6 ± 5 .5 6.6 ± 1.7a 10.6 ± 4 .6 9.8 ±  4.7
T H F s /T H E 1.22 ± 0 .3 4 1.34 ±  0.18 0.95 ±  0.28 1.12 ± 0 .4 0
Values are presen ted  as m ean ±  SD. B M I -  body  m ass index, T H F s -  te trahydrocortiso l +  allo-tetrahydrocortisol, 
T H E  = tetrahydrocortisone. aP <  0.05 vs placebo in sam e b lood  pressure group
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Fig 1 Normotensives Hypertensives
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Forearm  vascular resistance (FVR) in norm otensive (circles) and hypertensive subjects 
(squares) in placebo (open symbols) and GA-groups (closed symbols) during stepwise 
infusion o f cortisol into the brachial artery. Each dose was infused over a period o f  10 
minutes. Directly after the first cortisol infusion was finished, the subjects o f  the placebo­
groups received placebo and the subjects o f  the GA-groups received 500 m g GA.
groups. Results during the first and second vehicle infusion were 1.12 ± 0.18 and 1.47 ±
0.30 in the normotensive GA-group, 1.14 ± 0.13 and 1.08 ± 0.13 in the hypertensive 
placebo-group and 0.88 ± 0.07 and 0.95 ± 0.11 in the hypertensive GA-group, 
respectively (P=NS for all groups).
Effect of infusion of cortisol on forearm plasma steroids
In the normotensive placebo-group, the first intra-arterial cortisol infusion resulted in a 5 
to 6 fold increase of venous cortisone from 331 ± 38 nm ol/l during vehicle to 1894 ± 234 
nm ol/l during the highest cortisol dose. During vehicle infusion there was no difference 
in cortisone concentration between arterial and venous plasma (46 ± 5 and 50 ± 5 nmol/l, 
respectively). During cortisol infusion the venous cortisone concentration of 36 ± 3 
nm ol/l was significantly lower than the arterial cortisone concentration of 49 ± 4 nm ol/l 
(P<0,05), indicating a decrease of cortisone across the forearm. The venous - arterial 
cortisone differences were 4 ± 3 nm ol/l during vehicle and -13 ± 2 nm ol/l during 
cortisol-infusion (P<0.05). The venous cortisol/cortisone ratio of 54.2 ± 6.0 during
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infusion cortisol was significantly increased when compared to the ratio of 6.9 ± 0.7 
during vehicle (P<0.05).
Effect of glycyrrhetinic acid on forearm arterial and venous steroids during cortisol-infusion
Administration of GA did not alter either arterial or venous cortisol concentration during 
vehicle (table 2). GA significantly reduced cortisone concentrations in both venous and 
arterial plasma when compared to cortisone concentrations in subjects who received 
placebo, resulting in increased arterial and venous cortisol/cortisone ratios when 
compared to placebo.
During the highest cortisol infusion no significant differences in venous cortisol 
concentrations were found between subjects who had received placebo and those who 
had received GA. The arterial and venous cortisone concentrations during cortisol 
infusion were significantly lower after GA than after placebo. After GA, the venous 
cortisol/cortisone ratios during vehicle and during cortisol infusion were significantly 
higher than after placebo.
After GA, the venous — arterial difference for cortisone during vehicle was not different 
from the difference after placebo, values were 7 ± 2 GA and 6 ± 4 nm ol/l, respectively. 
During cortisol-infusion the venous — arterial difference for cortisone was 1 ± 1 after GA, 
which was significantly different from the difference of -6 ± 2 after placebo (P <0.05).
Effect of cortisol infusion on free cortisol and cortisone in venous plasma
The previous results showed that intra-arterial infusion of cortisol resulted in a decrease 
of venous cortisone concentrations. To analyse whether these changes were due to 
changes in free or in protein bound concentrations of plasma cortisone we measured free 
cortisone and free cortisol concentrations in venous plasma obtained during vehicle 
infusion and during infusion of cortisol. This was done in 10 normotensive participants in 
plasma samples obtained before administration of placebo (table 3). Cortisol infusion 
resulted in a decrease of total plasma cortisone, while free plasma cortisone did not 
change. During cortisol infusion, the fraction of cortisone that was bound to plasma 
proteins was decreased compared to protein-bound fraction during vehicle.
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T a b le  2. E ffec t o f g lycyrrhetin ic  ac id  on  arte ria l a n d  v enous p la sm a  ste ro id s  d u rin g  
co rtiso l-in fu sion  in  no rm o ten siv e  su b jec ts
Placebo (n=10) 
Vehicle Cortisol 35
Glycyrrhetinic acid (n=10) 
Vehicle Cortisol 35
Arterial cortisol (nmol/l) 234 ± 30 235 ± 21
Venous cortisol (nmol/l) 347 ± 55a 1900 ± 223b 348 ± 53a 1452 ± 194b
Arterial cortisone (nmol/l) 47 ± 6 47 ± 5 18 ± 2c 18 ± 2c
Venous cortisone (nmol/l) 53 ± 5 41 ± 4ab 25 ± 4ac 18 ± 3bc
Arterial cortisol/cortisone 5.2 ± 0.4 14.2 ± 1.2c
Venous cortisol/cortisone 6.6 ± 1.1a 47.5 ± 3.5b 15.6 ± 2.3c 90.6 ± 14.5bc
Venous — arterial cortisol (nmol/l) 113 ± 43 113 ± 36
Venous — arterial cortisone (nmol/l) 6 ± 4 -6 ± 2 7 ± 2 1 ± 1bc
Cortisol and cortisone in arterial and venous plasma during the second intra-arterial infusion o f 
vehicle or highest cortisol dose (35 pg per 100 ml forearm volume, infused over a period o f 10 
minutes). Placebo or 500 mg G A  was given orally 120 minutes before the start o f  the second 
cortisol infusion.
a P<0.05 versus result in arterial plasma within group. b P<0.05 versus vehicle within group. 
c P<0.05 versus placebo-group.
T a b le  3. E ffec t o f co rtiso l in fu sio n  on  to ta l a n d  free co rtiso n e  an d  co rtiso l in  venous 
p lasm a
Vehicle Cortisol 35 pg
Total cortisone (nmol/l) 49.6 ± 4.6 36.3 ± 3.4b
Free cortisone (nmol/l) 12.5 ± 0.9 12.4 ± 0.7
Bound cortisone (nmol/l) 37.1 ± 4.8 23.9 ± 3.7b
% bound cortisone 72.0 ± 4.0 60.8 ± 6.5a
Total cortisol (nmol/l) 331 ± 38 1894± 234b
Free cortisol (nmol/l) 19 ± 3 333 ± 39b
Bound cortisol (nmol/l) 312 ± 35 1561 ± 204b
% bound cortisol 94.3 ± 0.6 81.9 ± 1.7b
Total, free and bound concentrations o f cortisone and cortisol in venous plasma during intra- 
arterial infusion o f  vehicle and highest cortisol dose (35 pg per 100 ml forearm volume, infused 
over a period o f  10 minutes). Results were obtained in 10 norm otensive subjects during the first 
cortisol-infusion.
a P<0.05 versus vehicle within group. b P<0.01 versus vehicle within group.
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Intra-arterial infusion of cortisol resulted in an increase of free, bound and total plasma 
cortisol. The fraction of cortisol that was bound to plasma proteins decreased significantly 
during cortisol-infusion when compared to vehicle.
Discussion
This study demonstrates that infusion of cortisol in high concentrations directly into the 
brachial artery does not result in acute changes in FVR in both normotensive and 
hypertensive subjects. Even addition of GA, in an attempt to further increase the local 
availability of cortisol by decreasing local 11ß-HSD2 mediated conversion of cortisol to 
cortisone, did not alter FVR. Two hours after high dose cortisol-infusion we also found 
no changes in FVR as compared to baseline. Thus, we did not find any evidence for direct 
cortisol-mediated changes in vascular tone mediated by either rapid, nongenomic or 
classic, genomic pathways. Administration of GA resulted in an increase of the arterial 
cortisol/cortisone ratio, indicating inhibition of systemic 11ß-HSD2 mediated conversion 
of cortisol to cortisone. As cortisol infusion did not increase the cortisone gradient across 
the forearm, we did not find any indication for production of cortisone by 11ß-HSD2 
activity locally in the forearm. In fact, cortisol infusion resulted in a decrease of cortisone 
levels across the forearm, but that was caused by a decrease in the protein bound plasma 
cortisone while the concentration of free cortisone did not change.
In recent years it has been demonstrated that aldosterone administration can result in 
rapid non-genomic effects that are not mediated by classical corticosteroid receptors. In in 
vitro studies on vascular smooth muscle cells aldosterone administration resulted in a rapid 
increase of inositol triphosphate production and intracellular calcium concentration28;29. In 
a recent study similar rapid effects of cortisol on inositol triphosphate production and 
intracellular calcium concentration were reported19. These effects were only present 
during inhibition of 11 ß-HSD activity. In addition, intravenous administration of 
aldosterone resulted in a rapid increase of the systemic vascular resistance in humans in 
vivo30. In our study we did not find any indication of a rapid effect of cortisol on forearm 
vascular tone, as acute cortisol administration in the brachial artery did not affect FVR,
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even during inhibition of 11 ß-HSD activity. It is possible that only aldosterone, but not 
cortisol, exerts rapid vascular effects in vivo. The rapid in vivo effects of aldosterone were 
demonstrated as a change in systemic vascular resistance, but it was not specified in which 
part of the vasculature the changes occurred30. In our study we only looked at the effect 
of cortisol on FVR, so it can not be excluded that cortisol does affect vascular resistance 
in other parts of the body.
The effect of cortisol infusion directly into the brachial artery has been studied before by 
Walker et aP . In seven normotensive volunteers no effect of infusion of cortisol on 
forearm blood flow was found. In that study hydrocortisone-21-succinate (Solucortef) 
was used, which is an ester that needs to be hydrolyzed before cortisol becomes available, 
a process that may take several hours. In our study pure cortisol dissolved in ethanol was 
used, but we also did not find any changes in FVR either during or 2 hours after cortisol­
infusion. It has been demonstrated that topical administration of glucocorticoids increases 
cutaneous vasoconstrictor response31, and that inhibition of 11ß-HSD2 activity resulted in 
an increase of that response32. In neither the study by Walker et al. nor in our study any 
effect of cortisol on FVR was found both without and with inhibition of 11 ß-HSD 
activity. These studies focused on vascular tone in muscular and not in skin tissue, 
therefore it remains possible that the vascular sensitivity to cortisol and the effect of 
inhibition of local 11 ß-HSD activity may vary between tissues.
In our study we infused cortisol in increasing dosages over 2 periods of 30 minutes with 2 
hours in between. During these infusion we did not see any effect of cortisol on FVR. 
However, it is possible that this time period was too short to detect the effects of cortisol 
on FVR, both without and with inhibition of 11 ß-HSD-activity. Another limitation of our 
study is that cortisol-infusion may have resulted in smaller changes in FVR than we are 
able to detect in our study. Further, we did not study the effect of cortisol-infusion on 
vascular sensitivity to vasoconstrictive or vasodilatatory substances. Because of these 
limitations this study can not exclude that cortisol and /or 11 ß-HSD-activity may play a 
role in the pathogenesis of cortisol associated hypertension.
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In previous studies it was demonstrated that 11ß-HSD2 activity is decreased in a 
subgroup of patients with primary hypertension4;21. One of these studies suggested that 
the decrease of 11ß-HSD2 activity may be located outside the kidneys4. Based on the 
hypothesis that decreased 11ß-HSD2 activity may result in an increased sensitivity to 
rapid vascular effects of cortisol, we included patients with primary hypertension in the 
study. We did not find any differences in the effect of cortisol-infusion on either FVR or 
on cortisone gradient across the forearm between normotensive and hypertensive 
patients. In both normotensive and hypertensive participants, we did not find any changes 
in cortisol or cortisol across the forearm that indicated local activity of 11ß-HSD2. In 
addition, there was no difference in the effect of GA on arterial cortisol/cortisone ratio 
between normotensive and hypertensive participants, indicating that there was no 
difference in the inhibitory effect of GA on systemic 11ß-HSD2 activity between the two 
groups.
GA was used in this study to into inhibit 11ß-HSD2 activity. Administration of GA 
indeed resulted in an increase in arterial cortisol/cortisone ratio indicating inhibition of 
systemic 11ß-HSD2 activity, a finding that has previously been demonstrated in several 
studies12;18. Following GA, the venous cortisol/cortisone ratio during cortisol 
administration was also significantly increased compared to placebo-group. However, this 
can not be explained by inhibition of local 11ß-HSD2 activity by GA, because we did not 
find a lower venous — arterial difference in plasma cortisone after GA as compared to 
placebo.
Thus, using arterial cortisol infusion and administration of GA as tools to demonstrate 
local 11 ß-HSD activity, we were not able to demonstrate forearm vascular activity of 11 ß- 
HSD2. It can not be excluded that the methods we used may not have sufficient 
sensitivity to detect local 11 ß-HSD activity. Perhaps other tools, e.g. use of stable isotope 
methodology, as was recently used in a study of renal 11ß-HSD2 activity in vivo in man33, 
may be required to study whether or not activity of 11ß-HSD2 is present in vivo in 
forearm vascular tissues.
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We found that during arterial cortisol infusion the cortisone concentration in venous 
plasma decreased as compared to the concentration in arterial plasma. Further analysis 
showed that this decrease in the venous cortisone concentration was due to a decrease in 
the protein bound fraction of cortisone, not a decrease in the free plasma cortisone. It is 
known that the Km value for binding of cortisol to corticosteroid-binding globulin (CBG) 
is about 10-fold higher than the Km for cortisone (76 x 10-6 and 7.8 x 10-6 M-1, 
respectively)34. We therefore suggest that the reduction of protein bound cortisone during 
arterial cortisol infusion may result from displacement of cortisone away from CBG 
caused by the high concentration of free plasma cortisol. As the veno-arterial difference in 
total plasma cortisone concentration did not increase during cortisol infusion, the total 
cortisone content of the forearm did not decrease. We suggest that the initial increase of 
free cortisone may have resulted in diffusion or transportation of cortisone to the forearm 
tissues, explaining the decrease in total plasma cortisone concentration. In several studies 
changes in plasma cortisol-cortisone ratio or plasma cortisone have been interpreted as an 
indication of (changes in) 11 ß-HSD activity35;36. Our results demonstrate that infusion of 
cortisol may result in changes in plasma cortisone concentration that are not necessarily 
due to (changes in) 11 ß-HSD activity. Therefore, in situations where cortisol (or any other 
compound that may affect binding of cortisone to plasma proteins) is administered, 
changes in the total plasma cortisone concentration may not be used as an indicator for 
(changes in) 11 ß-HSD activity.
In conclusion, acute infusion of cortisol, both without and with inhibition of 11 ß-HSD 
activity, does not affect FVR both immediately and after 2 hours in normotensive and 
hypertensive subjects. We could not demonstrate in vivo activity of either 11ß-HSD1 or 
11ß-HSD2 in forearm vascular tissues. In situations were binding of cortisone to CBG 
may be affected, changes in cortisol/cortisone ratio or in plasma cortisone concentrations 
across a tissue or organ can not reliably be used to assess (changes in) 11 ß-HSD activity.
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Renal cortisol infusion and 11 ß-HSDs
Abstract
Introduction Cortisol is known to increase blood pressure. One possible mechanism is 
the reported increase in renal vascular resistance (RVR). It is unknown whether this is due 
to a direct effect o f cortisol on the kidneys. We studied the effect of infusion of cortisol 
directly into the renal artery on renal blood flow (RBF) and on renal 11 ß-hydroxysteroid 
dehydrogenase (11 ß-HSD) mediated conversion of cortisol to cortisone in patients with 
primary hypertension.
D esign and Methods Twenty-seven patients with primary hypertension participated in 
this study. Fifteen subjects received placebo and 12 patients received glycyrrhetinic acid 
(GA) 500 mg orally 2% hours before the study. After a 10 minutes infusion of glucose 
5%, cortisol was infused in stepwise increasing doses (0.625, 1.25 and 2.5 p,g/kg/minute), 
each for 10 minutes. At the end of each infusion step RBF was measured using the 
133Xenon wash-out technique. Plasma samples from the femoral artery and renal vein 
were taken for measurement o f cortisol and cortisone. Urine was collected for 
measurement o f steroid concentrations for 6 hours on the day before the infusion and for 
6 hours following the infusion.
Results After placebo, cortisol infusion did not change RVR, RBF or blood pressure. 
RVRs were 0.72 (0.45 - 0.89 (median (first and third quartiles)) ) and 0.71 (0.64 - 0.91) 
mm H g/m l per min per 100 ml tissue during infusion of glucose 5% and the highest 
cortisol dose, respectively (P=NS). In the GA-group cortisol infusion also did not change 
RVR, RBF or blood pressure. Cortisol infusion increased the venous — arterial difference 
in plasma cortisone across the kidney from 76 (40 - 115) to 138 (100 - 186) nm ol/l 
(P<0.05). It increased the cortisol/cortisone ratios in renal vein and in urine (both 
P<0.05). Administration of GA increased cortisol/cortisone ratios in peripheral and renal 
vein and in urine as compared to placebo.
Conclusion Acute infusion of cortisol in high doses directly into the renal artery in 
patients with primary hypertension did not affect RBF or RVR. Cortisol infusion resulted 
in increased cortisol-cortisone conversion by renal 11ß-HSD2, but the concurrent 
increase o f renal and urinary cortisol/cortisone ratio suggests relative insufficiency of 
renal 11ß-HSD2 activity due to enzyme saturation. This may enhance mineralocorticoid 
receptor stimulation by cortisol.
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Introduction
Hypertension is a well-known complication of cortisol excess. It is present in about 80% 
of patients with endogenous Cushing’s syndrome1. In normotensive subjects oral 
administration of cortisol 50 mg every 6 hours for 5 days increased systolic blood pressure 
by 10 mm Hg2. In addition, in patients with primary hypertension suppression of 
endogenous cortisol production by dexamethasone resulted in a fall in blood pressure3;4. 
This suggests that cortisol may play a role in the pathogenesis o f primary hypertension.
The mechanism by which cortisol causes an increase in blood pressure is not known 
precisely. One possibility is that cortisol increases blood pressure by stimulation of 
traditional cytosolic corticosteroid receptors. An alternative mechanism was suggested in a 
recent study that demonstrated rapid effects o f cortisol that are mediated by non-cytosolic 
receptors5. The clinical significance of these rapid effects is not known.
In the kidneys, access o f cortisol to the mineralocorticoid receptors is regulated by 11 ß- 
hydroxysteroid dehydrogenase type 2 (11ß-HSD2) activity. This isozyme converts cortisol 
to its inactive metabolite cortisone, thus preventing cortisol from binding to the 
mineralocorticoid receptor6;7. In immunohistochemical studies on human kidney, strong
11 ß-HSD2 immunoreactivity was found in distal tubules and collecting ducts8. Decreased 
activity o f 11ß-HSD2 may be either congenital or acquired (e.g. by intake of glycyrrhetinic 
acid (GA)) and results in free access o f cortisol to mineralocorticoid receptors, thus 
causing severe hypertension, salt retention and hypokalaemia9-11. The presence of 11 ß- 
HSD type 2 has been demonstrated in vascular smooth muscle cells (VSMCs) in human 
kidney8. Activity of 11 ß-HSD may affect cortisol-cortisone conversion in renal VSMCs 
and modulate local effects o f cortisol.
Direct effects o f cortisol on renal hemodynamics have been demonstrated in sheep, 
where infusion of cortisol intravenously or into the renal artery resulted in a rapid 
sustained increase o f renal blood flow (RBF) within 5 hours12;13. This effect was due to 
direct renal action involving nitric oxide13. In contrast, in humans there is some evidence 
to suggest that administration of cortisol is associated with an increase in renal vascular 
resistance (RVR). In normotensive volunteers, oral cortisol for 5 days resulted in increase
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of RVR that was accompanied by an increase in blood pressure and salt retention and by 
expansion of extracellular fluid and plasma volume2. There are however no studies in 
humans in which the direct effects of cortisol on renal vascular tone have been 
investigated.
The aim of the present study was to investigate the acute effect o f cortisol on RBF and 
RVR in patients with primary hypertension, and to evaluate whether this effect, if any, 
would be related to mineralocorticoid receptor stimulation. To this end, we infused 
cortisol into the renal artery with or without prior inhibition of 11ß-HSD2 activity by GA 
in untreated patients with primary hypertension. We used GA to maximize local 
availability of cortisol to glucocorticoid and, in particular, mineralocorticoid receptors. To 
evaluate the effects o f cortisol infusion and GA on renal 11ß-HSD2 activity we measured 
cortisol and cortisone across the kidney during cortisol infusion and in urine before and 
after cortisol infusion. We decided to perform these studies in patients with hypertension 
because there is data indicating that in some patients with primary hypertension 11 ß- 
HSD2 activity is decreased either within or outside the kidneys14;15. Effects of cortisol 
infusion and/or inhibition of 11ß-HSD2 activity on RVR or renal cortisol-cortisone 
conversion may therefore more readily be demonstrated in patients with hypertension. 
Secondly, as these patients were scheduled to undergo renal catheterisation to exclude 
renal artery stenosis, they would not be exposed to additional risks related to the 
catheterisation procedure.
Patients and Methods
Patients
Studies were carried out in 27 patients with hypertension in whom renal artery stenosis 
was suspected on clinical grounds, including persistent hypertension and/or deterioration 
of renal function during antihypertensive treatment. Patients with a serum creatinine level 
over 150 p,mol/l were excluded from participation because renal conversion of cortisol to 
cortisone is decreased in patients with renal impairment17. Administration of
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antihypertensive medication and consumption of GA-containing products were 
discontinued at least 3 weeks before the study.
In total, 27 patients were included: 15 received placebo and 12 received GA in double­
blind randomised fashion. A renal artery stenosis was present in five patients in the 
placebo-group and in one patient in the GA-group, therefore there were 10 patients in the 
placebo-group and 11 patients in the GA-group who did not have a renal artery stenosis. 
The study was approved by the medical ethics committee o f the University Hospital 
Maastricht and all patients gave written informed consent to this study.
All participants were asked to abstain from smoking, alcohol and caffeine for at least 12 
hours before the study. O n the morning of the study day between 07.00 h and 08.00 h, 
patients received either placebo or 500 mg GA (Omnilabo, Breda, The Netherlands) orally 
in a randomised double-blind study design. Two hours later the right renal artery and vein 
were cannulated via the femoral route. All measurements were performed in the right 
kidney to prevent admixion with adrenal venous blood as may occur with the left adrenal 
vein that drains into the left renal vein. RBF was measured using the 133Xenon wash-out 
technique as described earlier17;18. RBF values are expressed as mean blood flow per unit 
o f tissue mass (ml/min per 100 ml kidney tissue). The mean renal blood flow (MRBF) is 
the mathematical weighted average of the fast (cortical) and the slow (subcortical) flow 
component of the 133Xenon wash-out curve19.
After completion of all instrumentation, 150 minutes after administration of placebo or 
GA, blood from a peripheral vein was taken for measurement o f plasma cortisol and 
cortisone concentrations, and baseline RBF was measured. Next, an infusion of glucose 
5% in the right renal artery was started which was followed by infusion of cortisol, 
dissolved in glucose 5%, in three stepwise increasing concentrations (0.625, 1.25 and 2.5 
p,g/ml/kg body weight). Each infusion was maintained for 10 minutes at a constant flow 
rate o f 1.0 ml/min. Intra-arterial blood pressure and heart rate were monitored 
continuously. During the last 2 minutes of each infusion RBF was measured and blood 
samples were simultaneously collected from femoral artery and right renal vein for 
measurement o f plasma cortisol and cortisone concentrations. After the glucose 5%
84
Renal cortisol infusion and 11 ß-HSDs
infusion blood samples were also drawn for measurement of active plasma renin 
concentration (APRC) and plasma GA concentration. After all measurements had been 
completed, contrast angiography studies were performed to assess whether a renal artery 
stenosis was present or not.
Urine was collected for two periods of 6 hours each, the first starting at 10.00 a.m. on the 
day before the study and the second period started directly after the last infusion. In both 
urine collections, cortisol, cortisone and their tetrahydrometabolites were measured.
Laboratory measurements
Plasma creatinine was measured using the Jaffé method (Beckman). The APRC was 
measured by an IRMA method (Nichols Institute Diagnostics, San Clemente, California, 
USA)20. Cortisol and cortisone in both plasma and urine were measured by 
radioimmunoassay after extraction with organic solvents and paper chromatography21. 
Urinary 5ß-tetrahydrocortisol (5ß-THF), 5ß-tetrahydrocortisone (5ß-THE) and 5a- 
tetrahydrocortisol (5a-THF) were measured according to Weykamp et al.21, using a gas 
chromatograph equipped with a flame ionization detector (Carlo Erba Instruments 
HRGC 5300 Mega series; Rodano, Milan, Italy) and fitted with a WCOT fused-silica 
capillary column (Chrompack, Middelburg, The Netherlands, 25 m x 0.25 mm i.d. with a 
fill thickness of 0.12 p,m, liquid phase CP-SIL-5CB). Plasma GA concentration was 
measured using high performance liquid chromatography22. The lower limit of detection 
of GA was 10 ng/ml, and the intra-assay variation coefficient was 6.2 % at 0.103 p.g/ml 
and 0.3 % at 4.120 p,g/ml.
Calculations
Renal vascular resistance (RVR) was calculated as intra-arterial mean blood pressure 
(MAP) divided by MRBF.
Statistical analysis
Data are presented as medians and interquartile ranges unless otherwise indicated. Non- 
parametric tests with correction for multiple testing were used to compare placebo-group 
and GA-group, using Kruskal-Wallis (one-way analysis of variance) and Mann Whitney-U
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Table 1. Effect of glycyrrhetinic acid on renal haemodynamics and plasma steroids
Variable Placebo
(n=15)
Glycyrrhetinic acid 
(n=12)
Renal hemodynamics
MAP (mm Hg) 126 (114-143) 126 (109-134)
Heart rate (beats/minute) 77 (63-87) 66 (60-70)
RBF (m l/min per 100 ml tissue) 196 (137-259) 157 (83-211)
RVR (mm H g/m l per min per 100 ml tissue) 0.72 (0.45-0.91) 0.80 (0.63-1.45)
Plasma steroids
Cortisol peripheral vein (nmol/l) 500 (403-675) 600 (473-715)
Cortisone peripheral vein (nmol/l) 66 (56-74) 45 (40-56)a
Cortisol/cortisone peripheral vein 7.3 (5.8-11.8) 12.0 (9.6-18)a
Cortisol femoral artery (nmol/l) 470 (310-720) 495 (365-555)
Cortisone femoral artery (nmol/l) 62 (52-71) 49 (41-63)a
Cortisol/cortisone ratio femoral artery 9.3 (4.4-11.3) 9.8 (7.8-14.6)
Cortisol renal vein (nmol/l) 385 (235-638) 410 (305-570)
Cortisone renal vein (nmol/l) 150 (109-181) 128 (102-155)
Cortisol/cortisone ratio renal vein 2.6 (1.8-4.3)b 3.6 (2.5-4.7)b
Delta cortisone across right kidney (nmol/l) 76 (40-115) 82 (57-102)
Blood samples were taken and measurements were done during infusion o f  glucose 5% into the 
renal artery, 150 m inutes after oral administration o f  placebo or glycyrrhetinic acid (500 mg). 
MAP, m ean arterial pressure; RBF, renal blood flow; RVR, renal vascular resistance. D ata are 
expressed as medians (interquartile ranges). a: P<0.05 versus placebo-group (Mann W hitney U 
test), b: P <  0.05 versus value in femoral arterial plasma within group (Wilcoxon).
tests. For within group comparisons, Friedman’s two-way analysis of variance and 
Wilcoxon tests were used. P values <0.05 were considered statistically significant.
Results
Patients
There were no significant differences in baseline characteristics (mean ± SD) between 
placebo-group and GA-group. Data for both groups were: age 39 ± 11 and 44 ± 11 years, 
body mass index 29 ± 6 and 29 ± 5 kg/m 2, plasma creatinine 85 ± 19 and 94 ± 26 p,mol/l, 
systolic blood pressure 177 ± 26 and 176 ± 17 mm Hg and diastolic blood pressure 104 ±
12 and 101 ± 10 mm Hg, respectively. Data regarding renal hemodynamics at baseline are
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Renal blood flow (RBF, top panel), mean arterial blood pressure (MAP, middle panel) and renal 
vascular resistance (RVR, lower panel) in hypertensive patients during stepwise infusion of 
cortisol into the right renal artery. M easurements were started 150 m inutes after oral 
administration o f placebo (0, n=15) or 500 m g glycyrrhetinic acid (♦ , n=12). D ata are 
expressed as medians and interquartile ranges.
presented in table 1, there were no differences between groups. Also when only patients 
without a renal artery stenosis were considered no differences in baseline characteristics 
between placebo-group and GA-group were found.
Effects o f cortisol infusion on renal hemodynamics after placebo
The effects o f infusion of cortisol directly into the renal artery on RBF, MAP and RVR 
are shown in figure 1 (placebo-group). RBFs were 196 (137 - 259) and 185 (145 - 205) 
m l/m in per 100 ml tissue during infusion of glucose 5% and the highest cortisol dose, 
respectively (P=NS). Cortisol infusion did not change MAP. It also did not change RVR:
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Effect o f glycyrrhetinic acid on plasma steroid parameters in hypertensive patients. Placebo (0, 
n=15) or 500 mg glycyrrhetinic acid (♦ , n=12) was given orally 150 minutes before the start of 
the infusions. The upper panel represents the venous-arterial difference in plasma cortisone 
concentration across the right kidney. The other panels represent the cortisol/cortisone ratios in 
right renal vein (middle panel) and right femoral artery (lower panel). D ata are expressed as 
medians and interquartile ranges.
0.72 (0.45 - 0.89) and 0.71 (0.64 - 0.91) mm H g/m l per min per 100 ml tissue during 
infusion of glucose 5% and the highest cortisol dose, respectively (P=NS). When only 
patients without a renal artery stenosis were considered again no changes were found 
during cortisol infusion. RBFs were 218 (157 - 267) and 194 (132 - 212) m l/m in per 100 
ml tissue and RVRs were 0.62 (0.42 - 0.99) and 0.69 (0.53 - 1.01) mm H g/m l per min per 
100 ml tissue during infusion of glucose 5% and cortisol 2.5 ^g/kg/m in, respectively 
(P=NS). Again no effect o f cortisol infusion on MAP was found.
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T a b le  2. C ortiso l, co rtisone  a n d  th e ir  te trah y d ro m etab o lite s  in  u rin e  before  a n d  after 
in fu sio n  o f  cortiso l
Param eter Placebo-group (n=15) Glycyrrhetinic acid group (n=12)
Before infusion After cortisol 
infusion
Before infusion After cortisol 
infusion
Cortisol (nmol/l) 46 (20-81) 183 (94-380)a 33 (23-87) 323 (227-603)a
Cortisone (nmol/l) 149 (97-241) 321 (229-441)a 120 (99-253) 346 (191-433)a
Cortisol/cortisone 0.25 (0.17-0.41) 0.64 (0.36-0.96)a 0.24 (0.22-0.37) 1.28 (0.83-1.88)a’b
5ß-TH F (^m ol/l) 2.95 (1.73-4.45) 4.80 (2.70-10.18) 2.35 (1.10-3.70) 5.90 (3.63-9.20)a
5a-T H F  (^m ol/l) 2.95 (0.83-5.10) 2.65 (2.40-6.88) 1.60 (0.93-3.95) 3.30 (2.40-6.80)a
5ß-T H E  (^m ol/l) 3.75 (2.55-6.93) 6.70 (2.23-10.18) 2.80 (1.78-4.73) 4.60 (2.90-6.78)
(5ß-T H F+ 5a-
T H F )/5 ß -T H E
1.37 (0.90-1.71) 1.78 (1.26-2.14) 1.33 (0.86-1.79) 2.24 (1.58-3.09)a
Urine was collected during 6 hours on the day before the study and for 6 hours following 
infusion o f cortisol in the right renal artery. Placebo or glycyrrhetinic acid (500 mg) was given 
orally 150 m inutes before the start o f  the infusion. TH F, tetrahydrocortisol, TH E, 
tetrahydrocortisone. N o  differences between groups were found at baseline. a: P<0.05 versus 
before infusion within group (Wilcoxon), b: P<0.05 versus placebo-group (Mann-W hitney U).
Effects o f cortisol infusion on plasma steroids after placebo
During infusion of glucose 5%, the cortisol/cortisone ratio in renal vein plasma was 
significantly lower than that in femoral arterial plasma (table 1, placebo-group), suggesting 
that there was renal conversion of cortisol to cortisone by 11ß-HSD2. Infusion of cortisol 
into the renal artery resulted in a statistically significant increase of the cortisol 
concentration in renal vein plasma from 385 (235 - 638) to 1450 (1030 - 2600) nm ol/l 
during the highest cortisol dose (P<0.05). The plasma cortisone concentration in renal 
vein increased from 150 (109 - 181) to 225 (194 - 260) nm ol/l (P<0.05). In addition, 
infusion of cortisol resulted in a statistically significant increase o f the venous-arterial 
difference of cortisone across the right kidney (figure 2a). These data are compatible with 
increased renal production of cortisone. Infusion of cortisol into the renal artery also 
increased the cortisol/cortisone ratios in renal vein (figure 2b) and in arterial plasma
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(figure 2c). Similar results were found when only patients without a renal artery stenosis 
were considered.
Effects o f cortisol infusion on urinary steroids after placebo
Infusion of cortisol resulted in a statistically significant increase o f the urinary 
concentrations of cortisol and cortisone (table 2), the latter suggesting an increased renal 
production of cortisone after intrarenal infusion of cortisol. Moreover, after cortisol­
infusion the urinary cortisol/cortisone ratio increased significantly, suggesting that during 
infusion of cortisol into the renal artery the high arterial cortisol supply saturated the 
available capacity o f renal 11ß-HSD2. Infusion of cortisol did not significantly affect the 
urinary excretion o f the tetrahydrometabolites of either cortisol or cortisone. Similar 
results were found when only patients without a renal artery stenosis were considered.
Effects o f cortisol infusion on renal hemodynamics after G A
To evaluate the effect o f increased stimulation of mineralocorticoid receptors by cortisol 
on renal hemodynamics, we studied the effect of cortisol infusion on RBF and RVR 
during inhibition of 11 ß-HSD2 activity by GA. After administration of GA no difference 
in RBF as compared to placebo was found (figure 3). Also no effect o f GA on MAP or 
RVR could be demonstrated (table 1). In addition, GA did not significantly change the 
increase o f APRC across the kidney: 3.6 (1.1 - 12.1) 10-3 m U /l after placebo and 5.1 (0.2 - 
24.1) 10-3 m U /l after GA.
After GA, no effect of cortisol infusion on RBF, MAP or RVR was found (fig 1). In 
addition, during infusion of cortisol no significant differences in RBF, MAP or RVR were 
found between placebo-group and GA-group.
When only patients without a renal artery stenosis were considered again no differences in 
RBF, MAP and RVR were found between placebo and GA-group.
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Effects o f cortisol infusion on plasma steroids after G A
To verify that only patients in the GA-group had received GA we measured plasma GA 
concentrations. Glycyrrhetinic acid was not detectable in patients who received placebo, 
while GA concentration was 2.61 (1.95 - 3.99) p.g/ml in plasma from patients who 
received GA.
The cortisone concentrations in plasma from both peripheral vein and femoral artery 
were significantly lower in the GA-group than in the placebo-group (table 1). In addition, 
in the GA-group the cortisol/cortisone ratio in plasma from peripheral vein was 
significantly higher than in the placebo-group (fig 4), indicating decreased conversion of 
cortisol to cortisone following GA. No differences in cortisol/cortisone ratio in both 
arterial and renal vein plasma were found between placebo group and GA-group.
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Following GA, infusion of cortisol into the renal artery resulted in an increase o f the 
venous-arterial difference of cortisone across the kidney and of the cortisol/cortisone 
ratio in both renal vein and arterial plasma (fig 2). However, no significant differences 
between placebo-group and GA-group were found with respect to the effects of cortisol 
infusion on these variables.
After exclusion of those patients with a renal artery stenosis, the cortisol/cortisone ratio 
in peripheral vein was 9.7 (6.0 - 13.6) in the placebo-group and 12.0 (11.2 - 19.5) in the 
GA-group (P=0.09). The cortisone concentrations in peripheral venous and arterial 
plasma were significantly lower in the GA-group: in peripheral vein plasma they were 68 
(60 - 75) in the placebo-group and 47 (40 - 57) in the GA-group (P<0.05), and in arterial 
plasma 65 (56 - 76) and 52 (40 - 64), respectively, (P<0.05).
Effects o f cortisol infusion on urinary steroids after G A
In the GA-group, the infusion of cortisol into the renal artery caused an increase of the 
urinary excretion of cortisol and cortisone and in the cortisol/cortisone ratio (table 2). 
Following GA this ratio was significantly higher than after placebo, suggesting a lower 
available activity of renal 11ß-HSD2 in the GA-group than in the placebo-group. In the 
GA-group, the urinary excretion of the cortisol tetrahydrometabolites 5ß- and 5a-THF 
was significantly increased following cortisol-infusion, resulting in an increase of the 
urinary ratio o f cortisol tetrahydrometabolites over cortisone tetrahydrometabolites 
compared to the ratio before cortisol infusion.
After exclusion of those patients with a renal artery stenosis, the urinary 
cortisol/cortisone ratio following cortisol infusion was 1.38 (0.80 - 1.91) in the GA-group 
and 0.85 (0.36 - 1.00) in the placebo-group (P=0.08). In addition, in the GA-group the 
infusion of cortisol resulted in an increased urinary ratio o f cortisol tetrahydrometabolites 
over cortisone tetrahydrometabolites compared to the ratio before cortisol infusion. In 
the GA-group this ratio following cortisol infusion was higher than in the placebo-group: 
2.32 (1.49 - 3.29) and 1.42 (1.23 - 1.93), respectively (P<0.05).
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Discussion
In this study we demonstrate that acute in vivo infusion of cortisol in high concentrations 
into the renal artery o f patients with hypertension had no immediate vascular effect on 
renal blood flow or on renal vascular resistance either after placebo or after GA. Infusion 
of cortisol in patients with hypertension resulted in increments o f the cortisone gradient 
across the kidney and increased cortisone excretion in the urine. This indicates that 
conversion of cortisol to cortisone by renal 11ß-HSD2 activity is increased during cortisol 
infusion. In addition, the cortisol/cortisone ratios increased in renal vein and urine, 
suggesting that the available renal 11ß-HSD2 capacity was at least partly saturated during 
cortisol infusion. Administration of GA resulted in a lower available 11ß-HSD2 activity as 
reflected by the increased urinary cortisol/cortisone ratios.
There are no other studies in humans in vivo in which the direct effects o f cortisol infusion 
into the renal artery on renal hemodynamics were studied. In the present study, infusion 
o f cortisol in high concentrations directly into the renal artery did not change RBF or 
RVR within 30 minutes. In a previous study, Connell and co-workers demonstrated that 
oral administration of cortisol 50 mg 4 times daily to human volunteers for 5 days resulted 
in increased RVR2. There are several differences between that study and ours. In the study 
by Connell and co-workers, cortisol administration was continued for five days, whereas 
we infused cortisol for a total o f 30 minutes. In our study, RBF was measured using the 
133Xenon wash-out technique, whereas Connell and co-workers measured glomerular 
filtration rate and effective renal plasma flow using clearance of inulin and p- 
aminohippurate, respectively. Third, in contrast to Connell’s study, in which cortisol was 
given systemically, we administered cortisol directly in the renal artery. Finally, an 
important difference between the two studies concerns the study population. Connell et al. 
studied normotensive volunteers, whereas our study was carried out in patients with 
hypertension.
It can not be excluded that the response of renal blood vessels to cortisol differs between 
hypertensive patients and normotensive controls, and that cortisol-administration would 
have effects on RVR in normotensive subjects. To answer this question our study should 
have included a control group of normotensive subjects, but it was deemed ethically
93
Chapter 5
unacceptable to expose them to the risks o f this invasive study. In our study we also 
included patients with a renal artery stenosis, and it is conceivable that the response of 
vessels in patients with renal artery stenosis is different from that in patients with primary 
hypertension. However, we could not find any difference in the response to intra-arterial 
cortisol infusion between patients with a renal artery stenosis and those with primary 
hypertension.
In our study we did not find any evidence for rapid effects o f cortisol on RVR in vivo. It 
cannot be excluded that our method was not sensitive enough to detect the rapid effects. 
Further, there may be effects of cortisol that take several hours to occur because they are 
mediated by the classic cytosolic pathway. Indeed, in studies in sheep that demonstrated 
renal vasodilatation on cortisol, these effects started after 1 hour23. However, these longer 
lasting effects were not the focus o f our study. Unfortunately, no other data are available 
with respect to the effect o f cortisol on RVR in humans.
In the present study, GA was used to inhibit conversion of cortisol to cortisone by renal 
11ß-HSD2, in an effort to maximize exposure o f renal glucocorticoid and, in particular, 
mineralocorticoid receptors to cortisol. However, also following GA administration acute 
administration of cortisol did not change RVR.
Our data show that, in patients with primary hypertension, the cortisol/cortisone ratio in 
the renal vein is significantly lower than the ratio in arterial plasma, suggesting that 
cortisol is indeed converted to cortisone in the kidney. Renal conversion of cortisol to 
cortisone at baseline has been demonstrated previously24;25. In the present study we 
demonstrate that infusion of cortisol directly into the renal artery results in an increase of 
the venous-arterial difference in plasma cortisone concentration across the kidney. This 
indicates that at higher arterial cortisol concentrations there is sufficient renal 11 ß-HSD2 
capacity to increase renal cortisone production. Apparently there is a limit to the renal 
11 ß-HSD2 capacity to maintain similar cortisol/cortisone ratios in renal vein, as we also 
found an increase o f the cortisol/cortisone ratio in renal vein during cortisol infusion. 
This suggests that in situations of high arterial cortisol supply to the kidney, substrate 
overflow results in relatively deficient renal 11ß-HSD2 activity. In another study in patients 
with Cushing’s disease the urinary excretion of both cortisol metabolites and cortisone 
metabolites were increased, and the urinary ratio o f cortisol metabolites over cortisone
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metabolite was also increased when compared to controls26. These results again suggest 
relative deficiency of renal 11ß-HSD2 activity at high arterial cortisol concentrations.
Administration of GA resulted in an increase of the cortisol/cortisone ratios in peripheral 
venous plasma, indicating that systemic 11ß-HSD2 activity was inhibited10;11. In addition, 
the urinary cortisol/cortisone ratio following cortisol infusion was also increased in the 
GA-group when compared to the placebo-group, indicating that renal 11ß-HSD2 activity 
was also inhibited following GA-administration. In our study inhibition of 11ß-HSD2 
activity by GA combined with relative deficiency of renal 11ß-HSD2 activity during 
cortisol-infusion may have allowed inappropriate binding of cortisol to mineralocorticoid 
receptors. If  this situation remains for a prolonged period, this may result in 
mineralocorticoid hypertension, a mechanism that was first suggested by Ulick and co­
workers27.
It has been shown that binding of cortisol to the mineralocorticoid receptor results in 
retention of water and salt and an increase in blood pressure1;28. Several other mechanisms 
have also been implicated in the cortisol-mediated increase in blood pressure. Cortisol 
may affect vascular sensitivity to vasoactive agents as in human volunteers oral cortisol 
administration increased the dose-dependent vasoconstrictive effect of noradrenaline. It 
also impaired forearm cholinergic dilatation29. In addition, cortisol increased Angiotensin 
II receptor expression in cultured rat vascular smooth muscle cells30. In studies in sheep, 
glucocorticoids increase RBF, and this was mediated by mechanisms involving 
prostaglandins and N O 13. It is not known whether similar effects occur in the human 
kidney.
In conclusion, we have demonstrated that acute infusion of cortisol directly into the renal 
artery in patients with primary hypertension does not change RBF or RVR, even after 
administration of GA. Cortisol infusion results in increased cortisol-cortisone conversion 
by renal 11ß-HSD2, but this increased conversion may be insufficient due to enzyme 
saturation, resulting in cortisol-mediated stimulation of mineralocorticoid receptors. 
Administration of glycyrrhetinic acid results in a decrease o f renal 11 ß-HSD2 activity but
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did not affect RBF and RVR. The precise mechanisms involved in cortisol-mediated 
hypertension need further investigation.
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11 ß-HSDs and forearm vascular reactivity
Abstract
Introduction 11 ß-hydroxysteroid dehydrogenase isozymes (11 ß-HSDs) catalyze the 
interconversion of cortisol and inactive cortisone, thereby modulating the activation of 
corticosteroid receptors by cortisol. In animal studies, presence of 11 ß-HSD type 1 
(mainly converting cortisone to cortisol), and 11 ß-HSD type 2 (converting cortisol to 
cortisone only) has been demonstrated in vascular smooth muscle cells and endothelial 
cells, respectively. Cortisol enhances noradrenalin-induced arterial vasoconstriction. 
Inhibition of the activity of vascular 11 ß-HSDs by carbenoxolone may modulate access of 
cortisol to vascular glucocorticoid receptors, thus affecting endothelium-dependent and 
endothelium-independent vasoreactivity.
Methods Eight healthy normotensive male volunteers received carbenoxolone (100 mg 
t.i.d.) or placebo for two days in double blind cross-over design. We measured forearm 
blood flow by venous occlusion plethysmography after intra-arterial administration of 
acetylcholine (ACh, 7.5 and 15 p,g/ml), sodium nitroprusside (SNP, 1.6 and 3.2 p,g/ml), 
noradrenaline (20 and 40 ng/ml) and N-monomethyl-l-arginine (L-NMMA, 2 and 4 
^mol/ml), all infused at 1 ml/min.
Results: Percentage changes in flow ratio infused/non infused arm after infusion of 
highest dose of each drug (mean ± SEM) after administration of placebo or 
carbenoxolone, respectively, were as follows: ACh +249 ± 61 and +294 ± 75%; SNP 
+227 ± 44 and +248 ± 56%; noradrenaline -31 ± 6 and -28 ± 5%; L-NMMA -35 ± 4 and - 
34 ± 4%. No differences between placebo and carbenoxolone results were found.
Conclusion In normotensive human volunteers inhibition of 11 ß-HSD activity by 
carbenoxolone administration for 2 days does not result in increased vascular sensitivity 
to NA and/or decreased sensitivity to SNP or ACh. This does not exclude that long-term 
inhibition of vascular 11 ß-HSD activity may modulate vascular tone, but suggests that the 
effect may be indirect.
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Introduction
Glucocorticoids and mineralocorticoids are important in maintaining vascular tone1. In in 
vitro studies administration of cortisol and corticosterone increased noradrenaline-induced 
vasoconstriction in aortic strips from rabbit2;3 and rat4;5, and also in strips from human 
umbilical artery6. Similar effects were found in in vivo studies. In pigs administration of 
deoxycorticosterone acetate resulted in increased arterial vasoconstriction to 
noradrenaline7, while administration of a glucocorticoid receptor blocking agent blunted 
the pressor response to noradrenaline in anaesthetised rats8. In humans administration of 
cortisol resulted in increased arterial constriction in response to cold stimuli and intra- 
arterially administered noradrenaline9, and in impaired forearm vasodilatation on 
acetylcholine10.
The effect o f cortisol in various tissues is modulated by local glucocorticoid metabolism. 
11 ß-Hydroxysteroid dehydrogenases (11 ß-HSDs) catalyse the interconversion of cortisol 
and its inactive metabolite cortisone. In the kidney, 11 ß-HSD type 2 (11ß-HSD2) 
inactivates cortisol and thus protects mineralocorticoid receptors from cortisol11. 
Decreased activity o f this isozyme (e.g. in the apparent mineralocorticoid excess 
syndrome) results in severe cortisol-dependent mineralocorticoid excess and 
hypertension12-14.
11ß-HSDs are also present in blood vessels. In 1991, 11ß-HSD type 1 (11ß-HSD1) was 
described in rat vascular smooth muscle (VSM)5. Subsequent studies showed that 
administration of the enzyme inhibitors carbenoxolone or glycyrrhetinic acid, a 
constituent o f licorice, resulted in changes in vascular sensitivity to cortisol15-18. This was 
manifest as enhanced vasconstrictor sensitivity to noradrenaline. Since increased vascular 
sensitivity to noradrenaline is a known effect of cortisol administration, it was concluded 
that 11 ß-dehydrogenase activity protects vascular glucocorticoid receptors from cortisol.
More recently, it has emerged that 11ß-HSD1 usually converts cortisone to cortisol in vivo, 
rather than the reverse19;20. Activity o f 11ß-HSD1 is therefore predicted to enhance and 
not decrease glucocorticoid effects on blood vessels. However, 11ß-HSD2 (which was
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not cloned until 1994 and only converts cortisol to cortisone in vivo) has also been 
described in rat endothelial cells and in human VSM cells21;22. In 11ß-HSD2 knock-out 
mice the vascular sensitivity to noradrenaline was increased while the sensitivity to 
endothelium-derived NO was decreased. Relaxation responses to endothelium-dependent 
and -independent vasodilators were also impaired23. This suggests that activity of 11 ß- 
HSD2 may reduce glucocorticoid effects on blood vessels. In addition, in human arteries 
vascular 11ß-dehydrogenase activity also prevents cortisol from exerting rapid, non­
genomic effects on intracellular pH24.
Production of cortisone in the human forearm has been demonstrated in one study, 
indicating local 11 ß-dehydrogenase activity25. We hypothesized that inhibition of 11 ß- 
HSD2 activity might increase glucocorticoid effects on blood vessels resulting in 
increased adrenergic vasoconstriction and impaired cholinergic vasodilatation. To 
investigate the effect of inhibition of 11 ß-HSD isozymes on vascular function of human 
blood vessels in vivo, we have now examined the effect of carbenoxolone administration 
on endothelium-dependent and endothelium-independent vasoreactivity in healthy 
volunteers.
Methods
Subjects
Eight healthy normotensive male volunteers participated in the study. They were non­
smokers and did not take licorice or any drugs. Each volunteer gave written informed 
consent. The study was approved by the Lothian Research Ethics Committee.
All volunteers received carbenoxolone (100 mg orally every 8 hours on the two days 
before and the morning of the study day) or placebo in a randomised, double blind, cross 
over study design. Phases were separated by a wash-out period of at least two weeks. On 
the study day the volunteers abstained from alcohol and caffeine for at least 12 hours.
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The experiments started at 8.00 a.m. and were performed in a temperature controlled- 
room at 23o C.
Forearm blood flow measurements
Forearm blood flow studies were performed as described previously26;27. Briefly, subjects 
were in a supine position during the study. After local anaesthesia (lignocaine 1%), a 27 
gauge stainless steel sterile needle (Cooper’s Needle Works, Birmingham, UK) was 
introduced into the left brachial artery. Patency was maintained by infusion of 0.9% 
physiological saline (Baxter Healthcare Ltd) at a rate of 1 ml per minute. Forearm blood 
flow measurements started after an acclimatisation period of 30 minutes. Wrist cuffs were 
inflated to 200 mm Hg during 3-minute recording periods to exclude hand circulation. 
Forearm blood flow was recorded simultaneously in both forearms by venous occlusion 
plethysmography using mercury-in-silastic strain gauges (Hokanson EC4, D.E. Hokanson 
Inc., Washington D.C., USA). For each measurement, upper arm congesting cuffs were 
inflated to 40 mm Hg for 10 seconds in every 15 seconds. The average forearm blood flow 
for the final five recordings in each 3 minutes period was used to determine forearm blood 
flow.
Protocol
Cumulative dose responses were measured with infusions of ACh (acetylcholine, Miochol 
20 mg, OMJ Pharmaceuticals Inc., Puerto Rico, USA) 7.5 and 15 p,g/ml, SNP (Sodium 
Nitroprusside for Injection B.P. 50 mg, David Bull Laboratories, Victoria, Australia) 1.6 and 
3.2 p,g/ml, noradrenaline (Levophed, Sanophi Winthrop Limited, Surrey, U.K.) 20 and 40 
ng/m l and L-NMMA (N-monomethyl-l-arginine, Clinalpha, Switzerland) 2 and 4 
p,mol/ml. Ascorbic acid (0.1 ng/ml) was added to the noradrenaline solution to avoid 
oxidation. Each dose was infused at 1 ml/min for 6 minutes and forearm blood flow 
measurements were done during the last 3 minutes. Washout periods were allowed to allow 
return to baseline flow following infusion of ACh (20 minutes), SNP (25 minutes) and 
noradrenaline (30 minutes).
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Statistical Analysis
All data are presented as mean ± SE unless indicated otherwise. Differences within subject 
effects were analyzed by ANOVA for repeated measures and further analyzed with paired 
Student’s t-test if appropriate. Differences were considered to be significant at a P-value <
0.05 (two-sided).
Results
Participants' age was 28.8 ± 9.6 (mean ± SD) years, with body mass index 24.8 ± 4.1 kg/m 2, 
systolic blood pressure 127.9 ± 12.4 and diastolic blood pressure 73.5 ± 5.8 mm Hg. 
Carbenoxolone 100 mg every eight hours for 2 days did not change blood pressure or 
forearm blood flow at baseline.
The effect of carbenoxolone on endothelium-dependent and endothelium-independent 
vasoreactivity is shown in figure 1. Cholinergic vasodilatation was not different after 
carbenoxolone administration. The dose-dependent vasodilatation to SNP was not altered 
by carbenoxolone. Further, no changes in dose-dependent decrease of forearm blood 
flow to either noradrenaline or L-NMMA were found after carbenoxolone.
Discussion
In this study we examined the hypothesis that inhibition of 11 ß-HSD isozyme activity by 
carbenoxolone would result in increased exposure o f forearm vascular smooth muscle 
cells to cortisol. This would enhance forearm vascular sensitivity to noradrenaline and L- 
NMMA, and decrease forearm vasodilation on ACh and SNP. However, after 
administration of carbenoxolone to healthy volunteers for 2 days, we could not 
demonstrate any change in forearm vascular reactivity to noradrenaline, L-NMMA, 
acetylcholine or nitric oxide as compared to placebo.
In previous studies in human volunteers, administration of cortisol increased the dose- 
dependent vasoconstrictive effect o f noradrenaline9;28. Cortisol also impaired cholinergic 
dilatation10. Inhibition of 11 ß-HSD activity by carbenoxolone increased forearm
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Fig. 1 Change in forearm blood flow during intra-arterial infusion of acetylcholine, 
sodium-nitroprusside, noradrenaline and L-NMMA in 8 healthy subjects after placebo (□) 
or carbenoxolone (■) for 2 days. Results are expressed as the percentage change from 
baseline o f the ratio (flow in the perfused arm)/(flow in non-infused arm). Results are 
expressed as mean ± SE.
vasoconstriction to intra-arterially infused noradrenaline17. Further, administration of 
glycyrrhetinic acid potentiated the dermal vasoconstrictive effect o f cortisol15.
What factors may explain the lack of effect of carbenoxolone administration on forearm 
noradrenaline sensitivity in our study? First, in the studies demonstrating the increased 
noradrenaline sensitivity9;28 and decreased cholinergic dilatation10 after exogenous cortisol 
administration, cortisol was administered for at least 5 days. Therefore the duration 
o f the cortisol exposure might have been too short in our study. However, in in vitro 
studies glucocorticoid induced changes typically take only several hours29, and recently it
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was demonstrated that exposure o f cultured human coronary artery smooth muscle cells 
to cortisol for 24 hours resulted in increased binding of angiotensin II30. Further, cortisol- 
induced increase o f systolic blood pressure, which is thought to be caused by extra-renal 
mechanisms, is already present within 24 hours after start o f cortisol administration31. 
Therefore, if the cortisol-induced hypertension were mediated by glucocorticoid receptors 
in VSM, then the effects o f cortisol on vascular reactivity would probably take less than 2 
days to occur.
Secondly, the inhibition o f the 11 ß-HSD isozyme activities might have been too short. In 
in vivo studies in humans the effects o f glycyrrhetinic acid, a carbenoxolone analogue, 
orally on plasma cortisol/cortisone ratio is already present within two hours32, and the 
inhibition of renal 11 ß-HSD activity after licorice consumption is already detectable 
within one day33. These studies suggest that oral carbenoxolone administration for 2 days 
would be of sufficient duration to result in inhibition of 11 ß-HSD isozyme activities in 
humans in vivo.
The presence and activity o f 11 ß-HSD isozymes in vascular tissue has been demonstrated 
in several studies including rat and human tissues22;30;34;35. However, these findings have 
not always been consistent either throughout the vascular tree or between species. In 
1995 Krozowki et al.21 reported presence of 11ß-HSD2 in human VSM using 
immunohistochemical techniques. In a study on presence and activity of 11 ß-HSD 
isozymes in rat aortic tissue, Brem et al?6 demonstrated 11ß-HSD1 in both endothelial 
and VSM cells, 11ß-HSD2 could only be found in endothelial cells. In the study on 
human vascular tissue renal interlobular arteries were used, whereas in the rat study aortic 
tissue was used. Therefore, the presence of 11 ß-HSD isozymes may vary both with 
species, as was also demonstrated by Slight and colleagues37, and with vessel size. In our 
study we investigated the effect o f carbenoxolone on forearm blood flow, which is mainly 
determined by flow in skeletal muscle. In view of the previous data it is conceivable that 
physiological 11 ß-HSD activity is not present in arterioles supplying human forearm 
skeletal muscle, thus explaining the lack of effect o f carbenoxolone. Our study can not 
exclude that (patho-)physiological 11 ß-HSD activity may be relevant in other arterial 
systems in the human body.
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Finally, oral administration o f both mineralocorticoids (fludrocortisone) and 
glucocorticoids (dexamethasone) for 7 days resulted in increased forearm vasoconstriction 
to intra-arterially administered angiotensin II28. Recently it was demonstrated that cortisol 
induced an increase o f angiotensin II binding in cultured human coronary artery smooth 
muscle cells. This was enhanced by inhibition of 11ß-HSD2 activity and could be 
prevented by RU38486 (a glucocorticoid receptor blocker), but not by spironolactone (a 
mineralocorticoid receptor blocker)30. Therefore, the effect o f increased glucocorticoid 
exposure to vascular smooth muscle cells might also be mediated by other vasoactive 
agents including angiotensin II. In our study we did not investigate the effect of 11 ß-HSD 
inhibition on angiotensin II induced vasoconstriction.
Vascular 11 ß-HSD activity has been studied in several models for hypertension. Activity 
of 11 ß-HSD2 in mesenteric arteries was lower in spontaneously hypertensive rats than in 
normotensive Wistar-Kyoto rats38. In contrast, no difference in 11ß-HSD1 activity 
between spontaneously hypertensive rats and normotensive Wistar-Kyoto rats was found. 
In 11ß-HSD2 knock out mice vascular reactivity to noradrenaline is enhanced, while 
vasodilatation to ACh and SNP is impaired23. Blood pressure is increased in these mice. 
In primary hypertension in humans, extra-renal activity o f 11ß-HSD2 is decreased39. A 
functional relationship between diminished vascular 11ß-HSD2 activity and elevated 
blood pressure has not yet been demonstrated. This study suggests that (changes in) 11 ß- 
HSD activity in vascular tissue may not directly alter vascular resistance in human forearm 
skeletal muscles. However, this does not exclude that changes in 11 ß-HSD activity may 
indirectly affect vascular tone.
Activity o f 11ß-HSD1 results in amplification of glucocorticoid effects in liver and 
adipose tissue, and it has been suggested that inhibition of 11ß-HSD1 activity might be 
useful in treatment o f type 2 diabetes and obesitas20. Our results suggest that treatment 
with HSD-inhibitors would not result in adverse affects on vascular tone and blood 
pressure, but this remains to be confirmed for administration over longer periods of time.
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In conclusion, this study does not support the hypothesis that inhibition of 11ß-HSD2 
activity for 2 days results in increased vascular sensitivity to noradrenaline and/or 
decreased sensitivity to sodium nitroprusside or acetylcholine.
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Introduction (chapter 1)
Hypertension is an important risk factor for the development of cardiovascular disease. In 
most patients the cause of the high blood pressure is not known, and hypertension is 
categorised as ‘primary’ hypertension. In the last few years several studies have suggested 
a role for the 11 ß-hydroxysteroid dehydrogenase (11 ß-HSD) isozymes in the 
pathogenesis of primary hypertension. This thesis focuses on vascular and renal 11 ß-HSD 
activities in patients with primary hypertension.
Physiological function of the 11ß-hydroxysteroid dehydrogenase isozymes
The 11 ß-HSD isozymes catalyze the dehydrogenation of the glucocorticoids cortisol (in 
humans) and corticosterone (in rodents) to their inactive 11-keto products cortisone and 
11-dehydrocorticosterone as well as the reverse reductive reaction. Two isozymes have 
been described. 11 ß-HSD type 1 is a bidirectional isozyme that is highly expressed in the 
liver where it mainly converts cortisone to cortisol. 11 ß-HSD type 2 only has 
dehydrogenase activity converting cortisol to cortisone. This isozyme is crucial in 
preventing stimulation of mineralocorticoid receptors in the kidney by cortisol. The 
conversion of cortisol to cortisone and vice versa is also known as the cortisol-cortisone 
shuttle.
In the kidney, aldosterone stimulates mineralocorticoid receptors resulting in retention of 
Na+ and H 2O and excretion of K+. This results in an increase of blood pressure. Cortisol 
similarly has a high affinity for the mineralocorticoid receptors. The plasma concentration 
o f cortisol is about a 100-fold higher than the plasma concentration of aldosterone. In 
normal circumstances stimulation of the renal mineralocorticoid receptors by cortisol is 
prevented by activity o f 11ß-HSD2. Activity o f this isozyme results in conversion of 
cortisol to cortisone, thereby preventing occupancy of mineralocorticoid receptors by 
cortisol. Cortisone does not bind to mineralocorticoid receptors and can therefore not 
stimulate these receptors. In situations with reduced renal 11ß-HSD2 activity, cortisol 
does stimulate the mineralocorticoid receptors. This results in a hypermineralocorticoid 
state, consisting of hypokalaemia, hypertension and low plasma aldosterone.
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In most studies renal 11ß-HSD2 activity has been assessed by measuring the urinary ratio 
of cortisol metabolites (tetrahydrocortisol and allo-tetrahydrocortisol) over the cortisone 
metabolite tetrahydrocortisone. An increase of this ratio would indicate decreased activity 
of renal 11ß-HSD2. Two situations have been described in which renal activity o f 11 ß- 
HSD2 is reduced. First, renal 11 ß-HSD2 activity may be reduced due to mutations in the 
gene coding for 11ß-HSD2 activity. This is known as the Apparent Mineralocorticoid 
Excess (AME) syndrome and results in severe hypokalaemic hypertension in young 
children. Second, 11ß-HSD2 activity is inhibited by glycyrrhetinic acid (GA), the active 
ingredient o f licorice. Therefore consumption of 50-100 grams licorice per day may also 
result in acquired hypokalaemic hypertension.
11ß-HSD activity and primary hypertension
The possible role of decreased activity o f 11 ß-HSD, in particular type 2, in the 
pathogenesis of essential hypertension has been investigated in a number o f studies. 
Analysis o f the urinary corticosteroid excretion pattern in a group of hypertensive patients 
provided support for a small but significant decrease in the activity o f 11ß-HSD2 as 
compared to results in a control group. In two other studies using a similar method no 
difference in 11ß-HSD2 activity was found between primary hypertensive patients and 
normotensive controls. However, in one of these studies the plasma half-life of 11a-[3H]- 
cortisol was prolonged in a subgroup of patients, suggesting decreased extrarenal 11 ß- 
HSD activity. These studies suggest that it is possible that in primary hypertension the 
activity of 11ß-HSD2 is decreased compared to normotensive controls, and that the 
defect may be located either in or outside the kidneys.
In several in vitro studies the presence of both 11ß-HSD1 and 11ß-HSD2 has been 
demonstrated in vascular tissue. In 11ß-HSD2 knock-out mice, the vasoconstrictive effect 
o f noradrenaline was increased, while the endothelial production of NO, a vasodilatator, 
was decreased. However, the physiological role o f the 11 ß-HSD isozymes in the 
vasculature is unknown. It is also not known whether the vascular activity o f these 
isozymes is decreased in hypertensive patients as compared to normotensive controls.
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Based on the possible decrease of 11 ß-HSD activity in hypertensive subjects, we 
hypothesized that activity o f the 11 ß-HSD isozymes is decreased in the blood vessels in 
patients with primary hypertension. Therefore these patients might be more sensitive to 
the vascular effects o f cortisol infusion. In addition, we hypothesized that patients with 
primary hypertension might be more susceptible to the inhibitory effect of GA on 11 ß- 
HSD2 activity.
The studies described in this thesis focussed on the following questions:
1. What are the immediate and direct effects o f arterial cortisol infusion on forearm and 
renal vascular resistance, both without and with inhibition of 11 ß-HSD activity? The 
forearm studies were performed in both normotensive volunteers and hypertensive 
patients. The renal studies were carried out in patients with primary hypertension.
2. What is the activity o f the 11 ß-HSD isozymes in the forearm and kidney, both without 
and with inhibition of 11 ß-HSD activity by GA? Activity o f 11 ß-HSD was assessed by 
measuring the plasma concentrations of cortisol and cortisone across a forearm and 
across a kidney. This was done both at baseline and during intra-arterial cortisol 
infusion.
3. What is the effect of inhibition of 11 ß-HSD activity on forearm vascular sensitivity to 
the physiological vasoconstrictor noradrenaline and to endothelium-dependent and 
endothelium-independent vasoactive agents in normotensive volunteers?
Measurement of glycyrrhetinic acid in plasma (chapter 2)
In the forearm and renal studies we used GA to inhibit the activity o f 11 ß-HSD. In all 
participants we measured plasma concentrations o f GA. This was done for two reasons. 
First, it is important to verify that the participants had not consumed licorice or any other 
GA-containing products at the time of entering the study. Second, we wanted to study the 
relation between the plasma GA concentration and the plasma cortisol/cortisone ratio (as 
an estimate o f 11 ß-HSD activity). We developed a new method for measurement o f 18ß- 
glycyrrhetinic acid in plasma or serum based on solid-phase extraction and subsequent
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HPLC (high pressure liquid chromatography) analysis. The method is much easier to carry 
out than previously described methods and has similar sensitivity and accuracy.
Immediate effects o f arterial cortisol infusion and inhibition of 11ß-HSD activity 
on forearm (chapter 3 and 4) and renal (chapter 5) vascular resistance
Forearm studies: in 20 normotensive volunteers we measured forearm vascular resistance 
both before and after inhibition of 11 ß-HSD activity by GA. A similar study was done in 
subjects with primary hypertension. No effect o f GA on forearm vascular resistance could 
be demonstrated in normotensive or in hypertensive subjects. This indicates either that 
vascular 11 ß-HSD activity does not affect forearm vascular resistance at all, or that 
inhibition of vascular 11 ß-HSD activity results in changes in vascular resistance that are 
too small to be detected with the method we used.
Next, we studied the acute effect of infusion of cortisol in three stepwise increasing doses, 
each infused over a 10 minute period, on forearm vascular resistance. This was done both 
with and without inhibition of 11 ß-HSD activity by GA in normotensive and 
hypertensive subjects. In both the normotensive and the hypertensive placebo-groups, 
infusion of cortisol did not change forearm vascular resistance either acutely or after two 
hours. Also after inhibition of 11 ß-HSD activity by GA, cortisol did not alter forearm 
vascular resistance in either group. This suggests that cortisol does not directly change 
forearm vascular tone either by rapid, nongenomic, or by classic genomic pathways.
Renal studies: in hypertensive patients the right renal artery and vein were cannulated via 
the femoral route. After 10 minutes infusion of glucose 5%, cortisol was infused intra- 
arterially in three increasing doses, each for 10 minutes. At the end of each infusion step 
the renal blood flow was measured using the 133Xenon wash-out technique. Infusion of 
cortisol did not alter renal vascular resistance. A similar protocol was also performed in a 
group of hypertensive patients who had received GA about 150 minutes before the start 
o f the cortisol infusion. Inhibition of 11 ß-HSD activity by GA did not change renal 
vascular resistance either before or during cortisol infusion. This suggests that cortisol 
does not directly alter renal vascular tone.
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Immediate effects of cortisol infusion on forearm (chapter 4) and renal (chapter 5) 
activity of the 11ß-HSD isozym es, both before and after 11ß-HSD inhibition
In our studies we did not directly measure activity of the 11 ß-HSD isozymes in either the 
kidney or the forearm. We measured the arterial and venous plasma concentrations of 
cortisol and cortisone and calculated the arterial and venous cortisol/cortisone ratios. 
These results were used to assess local activity o f the 11 ß-HSD isozymes in a specific 
organ.
Forearm studies: First we assessed local activity o f the 11 ß-HSD isozymes before and 
after administration of GA. After placebo there was no significant venous - arterial 
difference in the plasma concentration of either cortisol or cortisone across the forearm in 
both normotensive and hypertensive subjects. After GA administration we also did not 
find a significant venous - arterial difference across the forearm for either cortisol or 
cortisone, indicating that there was no local activity o f the 11 ß-HSD isozymes in either 
normotensive or primary hypertensive subjects. This suggests that there is no activity of the 
11 ß-HSD isozymes in the forearm vasculature at all, although it remains possible that their 
activity is too small to be detected by measuring arterial to venous changes in plasma 
cortisol, cortisone or the cortisol/cortisone ratio. Administration of GA did result in an 
increase o f the cortisol/cortisone ratio in arterial plasma and saliva, indicating inhibition 
o f 11ß-HSD2 activity both systemically and in the salivary glands, a specific 
mineralocorticoid target organ. In addition, there was no difference in the incremental 
effect of GA on the plasma cortisol/cortisone ratio between normotensive and 
hypertensive participants, indicating that there is no difference in the sensitivity of 11 ß- 
HSD2 activity to GA between these two groups.
Next, we studied forearm vascular activity o f the 11 ß-HSD isozymes during infusion of 
cortisol, both after placebo and after administration of GA. Infusion of cortisol did not 
increase the cortisone gradient across the forearm, also supporting the absence of activity 
o f 11ß-HSD2 in the forearm.
Renal studies: plasma concentrations o f cortisol and cortisol in the femoral artery and 
right renal vein were measured in patients with primary hypertension both before and 
during infusion of cortisol directly in the renal artery. Before cortisol-infusion there was
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an increase o f the plasma concentration of cortisone across the kidney, and a decrease of 
the cortisol/cortisone ratio across the kidney, indicating renal conversion of cortisol to 
cortisone by 11ß-HSD2. Infusion of cortisol in the renal artery resulted in an increment 
of the cortisone gradient across the kidney and in an increased cortisone excretion in the 
urine. This indicates that conversion of cortisol to cortisone by renal 11ß-HSD2 activity 
was increased during cortisol infusion. In addition, the cortisol/cortisone ratios increased 
further in renal vein and urine. These results suggest that the production of cortisone in 
the kidney is increased at a high arterial supply of cortisol, but that the conversion of 
cortisol to cortisone by renal 11ß-HSD2 is relatively insufficient at an increased supply of 
cortisol. This may result in stimulation of renal mineralocorticoid receptors by cortisol.
Administration of GA resulted in an increase of the cortisol/cortisone ratio in urine. This 
suggests that administration of GA did indeed result in inhibition of renal 11ß-HSD2 
activity. However, we did not find any effect of GA on the arterio-venous difference of 
cortisone across the kidney both before and during cortisol-infusion. This suggests that 
the inhibitory effect o f GA on renal 11ß-HSD2 activity may be limited. Alternatively, the 
dose of GA may have been too low to result in sufficient inhibition of renal 11ß-HSD2 
activity.
Effect o f cortisol infusion on free and protein bound fractions of plasma cortisone
Infusion of cortisol in the brachial artery resulted in an increase o f the cortisol/cortisone 
ratio in plasma from the brachial vein. This was not only caused by the expected increase 
o f cortisol due to arterial infusion, but also due to a decrease o f the cortisone 
concentration in venous plasma compared to arterial plasma. We found that the decrease 
in the venous cortisone concentration could be attributed to a decrease in the protein 
bound fraction of cortisone, not to a decrease in free plasma cortisone. This indicates 
that, in situations were binding of cortisone to corticosteroid-binding globulin may be 
affected, changes in cortisol/cortisone ratio or in plasma cortisone concentrations across 
a tissue or organ can not reliably be used to assess (changes in) 11 ß-HSD activity.
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11ß-hydroxysteroid dehydrogenase activity and forearm vascular reactivity (chapter 6)
The 11 ß-HSD isozymes modulate local concentrations o f cortisol. It is known that 
cortisol enhances noradrenaline-induced arterial vasoconstriction, decreases vascular N O ­
production and impairs forearm vasodilatation by acetylcholine. Inhibition of the activity 
of vascular 11 ß-HSDs by carbenoxolone has also resulted in increased vasoconstriction 
on noradrenaline. This may have been mediated by increased access o f cortisol to 
glucocorticoid receptors. We studied the effect o f inhibition of 11 ß-HSD activity by 
carbenoxolone on forearm vascular reactivity in healthy normotensive male volunteers. 
Administration of carbenoxolone did not alter the effects of intra-arterial administration 
of acetylcholine (ACh), sodium nitroprusside (SNP), NA and N-monomethyl-l-arginine 
(L-NMMA, an inhibitor of NO synthase). Therefore in normotensive human volunteers 
inhibition of 11 ß-HSD activity by carbenoxolone administration for 2 days does not 
result in increased vascular sensitivity to NA and/or decreased sensitivity to SNP or ACh. 
This does not exclude that long-term inhibition of vascular 11 ß-HSD activity may 
modulate vascular tone.
Conclusions
1. Inhibition o f 11 ß-HSD activity by GA does not affect forearm vascular resistance 
in normotensive or hypertensive individuals nor does it affect renal vascular 
resistance in hypertensive individuals.
2. Short-term intra-arterial infusion of cortisol in the forearm or the kidney does not 
immediately increase forearm or renal vascular resistance, both without and with 
inhibition of 11 ß-HSD activity.
3. Activity o f the 11 ß-HSD isozymes in forearm vascular tissue could be 
demonstrated neither in normotensive nor in hypertensive subjects.
4. At a high arterial supply of cortisol there is an increase in the conversion of 
cortisol to cortisone by renal 11ß-HSD2 activity in patients with hypertension. 
However, the conversion of cortisol to cortisone by renal 11ß-HSD2 is relatively 
insufficient at an increased supply of cortisol.
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5. Patients with primary hypertension do not have a decreased activity o f 11 ß-HSD2 
nor is there an increased sensitivity o f 11ß-HSD2 to inhibition by glycyrrhetinic 
acid.
6. Infusion of cortisol results in a decrease o f the protein bound fraction of cortisone 
in plasma, therefore a decrease of cortisone across an organ during cortisol 
infusion does not necessarily reflect local activity of 11 ß-HSD.
7. In normotensive volunteers, short-term inhibition of 11 ß-HSD activity for 2 days 
does not affect forearm vasoreactivity to NA, L-NMMA, SNP or ACh.
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Samenvatting en conclusies
Inleiding (hoofdstuk 1)
Hoge bloeddruk is een belangrijke risicofactor voor het ontstaan van hart- en vaatziekten. 
In het merendeel van de patienten is de oorzaak van de hoge bloeddruk onbekend, de 
hoge bloeddruk wordt dan primaire o f ‘essentiele’ hypertensie genoemd. Gedurende de 
laatste jaren hebben verschillende studies gesuggereerd dat de 11 ß-hydroxysteroid 
dehydrogenase (11 ß-HSD) isoenzymen een rol zouden kunnen spelen in het ontstaan van 
primaire hypertensie. Dit proefschrift concentreert zich op de rol van de vasculaire en 
renale activiteit van 11 ß-HSD in patienten met primaire hypertensie.
Fysiologische funktie van de 11ß-HSD isoenzymen
De 11 ß-HSD isoenzymen kataliseren zowel de dehydrogenatie van de glucocorticoiden 
cortisol (in de mens) en corticosteron (in knaagdieren) tot hun inaktieve 11-keto- 
produkten cortison en 11-dehydrocorticosteron als de omgekeerde reduktie reactie. Twee 
isoenzymen zijn beschreven. 11 ß-HSD type 1 is een bidirectioneel isoenzym dat sterk tot 
expressie wordt gebracht in de lever waar het voornamelijk cortison omzet in cortisol. 
11 ß-HSD type 2 heeft alleen dehydrogenase activiteit, resulterend in omzetting van 
cortisol in cortison. Dit isoenzym is cruciaal in het voorkómen van stimulatie van 
mineralocorticoidreceptoren in de nier door cortisol. De omzetting van cortisol in 
cortison en omgekeerd staat bekend als de ‘cortisol-cortisone shuttle’.
In de nier stimuleert aldosteron de mineralocorticoidreceptoren wat leidt tot het 
vasthouden van Na+ en H 2O en het uitscheiden van K+. Tevens leidt dit tot een 
verhoging van de bloeddruk. Cortisol heeft eveneens een hoge affiniteit voor de renale 
mineralocorticoidreceptoren. De plasmaconcentratie van cortisol is ongeveer honderd 
maal hoger dan die van van aldosteron. In normale omstandigheden wordt stimulatie van 
de mineralocorticoidreceptoren door cortisol echter voorkómen door 11ß-HSD2. Dit 
enzym zorgt namelijk voor een snelle omzetting van cortisol in cortison, waardoor 
stimulatie van de mineralocorticoidreceptoren door cortisol voorkómen wordt. Cortison 
kan niet binden aan mineralocorticoidreceptoren en deze dus niet stimuleren. In 
omstandigheden waarin de renale activiteit van 11ß-HSD2 is afgenomen kan het niet 
omgezette cortisol wel de mineralocorticoidreceptoren stimuleren. Dit leidt tot een
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situatie van verhoogde mineralocorticoide activiteit, bestaande uit hypokaliemie, hoge 
bloeddruk en een verlaagd aldosteron in plasma.
In de meeste studies wordt de renale activiteit van 11ß-HSD2 geschat door het meten van 
de verhouding van renaal uitgescheiden cortisolmetabolieten (tetrahydrocortisol en allo- 
tetrahydrocortisol) en de cortisonmetaboliet tetrahydrocortisone. Een toename van deze 
verhouding wijst op een afgenomen activiteit van 11ß-HSD2 in de nier. Er zijn twee 
situaties beschreven met een afgenomen activiteit van 11ß-HSD2 in de nier. Ten eerste 
kan de activiteit van 11ß-HSD2 in de nier afgenomen zijn ten gevolge van mutaties in het 
gen dat codeert voor de activiteit van 11ß-HSD2. Dit staat bekend als het ‘Apparent 
Mineralocorticoid Excess’ (AME) syndroom en leidt tot sterk verhoogde bloeddruk met 
hypokaliemie bij jonge kinderen. Daarnaast wordt de activiteit van 11ß-HSD2 geremd 
door glycyrrhetinezuur (GA), het aktieve bestanddeel van drop. De consumptie van 50­
100 gram drop per dag kan zo leiden tot een verworven vorm van hoge bloeddruk met 
hypokaliemie.
11ß-HSD activiteit en primaire hypertensie
In verschillende studies is onderzoek gedaan naar de mogelijke rol van afgenomen 
activiteit van 11 ß-HSD, in het bijzonder van type 2, in de pathogenese van primaire 
hypertensie. In een van deze studies wees het uitscheidingspatroon van de 
corticosteroiden in de urine in hypertensiepatienten op een kleine, maar significante 
afname van 11ß-HSD2 activiteit in vergelijking met een controlegroep. In twee andere 
studies, waarin een vergelijkbare onderzoeksmethode werd gebruikt, werd geen verschil in 
11ß-HSD2 activiteit gevonden tussen patienten met hoge bloeddruk en controle- 
personen met een normale bloeddruk. In een van deze studies was de halfwaarde tijd van 
11a-[3H]-cortisol toegenomen in een deel van de patienten, passend bij een verminderde 
11 ß-HSD activiteit buiten de nier. Deze studies suggereren dat de activiteit van 11 ß- 
HSD2 mogelijk verminderd is bij patienten met verhoogde bloeddruk in vergelijking met 
controle-personen met een normale bloeddruk. De studies suggereren tevens dat de 
verminderde 11 ß-HSD activiteit zowel binnen als buiten de nieren gelokaliseerd zou 
kunnen zijn.
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In meerdere in vitro studies is de aanwezigheid van zowel 11ß-HSD1 als 11ß-HSD2 
aangetoond in de wand van bloedvaten. In 11 ß-HSD2 knock-out muizen is de 
vaatvernauwende werking van noradrenaline toegenomen, terwijl de productie van het 
vaatverwijdende N O  in het endotheel afgenomen is. Het is echter niet bekend wat de 
fysiologische rol van de 11 ß-HSD isoenzymen in de vaatwand is. Verder is het ook 
onbekend of de activiteit van deze isoenzymen in de vaatwand afgenomen is in patienten 
met primaire hypertensie in vergelijking met controle-personen met normale bloeddruk.
Op grond de eerder beschreven mogelijke afname van 11 ß-HSD activiteit bij patienten 
met hoge bloeddruk formuleerden wij de hypothese dat dit onder andere gelocaliseerd 
zou kunnen zijn in de vaatwand van patienten met hoge bloeddruk. Dit zou dan kunnen 
leiden tot verhoogde gevoeligheid voor de vasculaire effekten van cortisol bij deze groep 
patienten. Daarnaast veronderstelden wij dat de patienten met verhoogde bloeddruk meer 
gevoelig zouden zijn voor het remmende effect van GA op 11 ß-HSD2 activiteit.
De onderzoeken beschreven in dit proefschrift hadden de volgende vraagstellingen:
1. Wat zijn de onmiddellijke en direkte effekten van arteriele infusie van cortisol op de 
vaatweerstand in de onderarm en de nier, zowel zonder als met remming van de 
activiteit van 11 ß-HSD? De onderarmsstudies werden verricht bij een groep 
vrijwilligers met normale bloeddruk en bij patienten met verhoogde bloeddruk. De 
nierstudies werden uitgevoerd in patienten met een verhoogde bloeddruk.
2. Wat is de activiteit van de 11 ß-HSD isoenzymen in de onderarm en nier, zowel 
zonder als met remming van de activiteit van 11 ß-HSD door GA? Hiervoor werd 
gebruikt gemaakt van de plasmaconcentraties van cortisol en cortison in de 
onderarmsslagader en onderarmsader en in nierslagader en nierader. Dit werd gedaan 
voor en tijdens infusie van cortisol in de slagaders van onderarm en nier.
3. Wat is het effekt van remming van de 11 ß-HSD activiteit op de gevoeligheid van de 
onderarmsvaatwand voor de fysiologische vasoconstrictor noradrenaline en voor 
endotheel-afhankelijke en endotheel-onafhankelijke vasoaktieve stoffen bij vrijwilligers 
met een normale bloeddruk?
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M eting van glycyrrhetinezuur in plasma (hoofdstuk 2).
In de onderarms- en nierstudies gebruikten wij GA om de activiteit van 11 ß-HSD te 
remmen. Bij alle deelnemers werd de plasmaconcentratie van GA gemeten. Dit had twee 
doelen. Ten eerste is het belangrijk om er zeker van te zijn dat de deelnemers geen drop 
o f andere glycyrrhetinezuur bevattende produkten hadden ingenomen bij de start van de 
studie. Ten tweede wilden we de relatie bestuderen tussen de plasma GA concentratie en 
de cortisol/cortison ratio in plasma (als maat voor de 11 ß-HSD activiteit). Er werd een 
nieuwe methode ontwikkeld voor de vaste fase extractie van 18ß-glycyrrhetinezuur uit 
plasma of serum met vervolgens analyse middels HPLC (hoge druk vloeistof 
chromatografie). De methode is veel eenvoudiger uit te voeren dan eerder beschreven 
methoden en heeft een vergelijkbare gevoeligheid en precisie.
Onmiddellijke effekten van infusie van cortisol in de slagader en remming van de 
11ß-HSD activiteit op de vaatweerstand in onderarm (hoofdstuk 3 en 4) en nier 
(hoofdstuk 5)
Studies in de onderarm: in een groep van 20 vrijwilligers met een normale bloeddruk werd 
de vaatweerstand in de onderarm gemeten, zowel voor als tijdens remming van 11 ß-HSD 
activiteit door GA. Een vergelijkbare studie werd verricht in een groep individuen met 
verhoogde bloeddruk. In beide groepen resulteerde toediening van GA niet in een 
verandering van de vaatweerstand in de onderarm. Dit suggereert dat activiteit van 11 ß- 
HSD de onderarmsvaatweerstand niet beinvloedt of dat remming van de vasculaire 11 ß- 
HSD activiteit leidt tot een verandering in onderarmsvaatweerstand die te gering is om te 
kunnen detecteren met de door ons gebruikte onderzoeksmethode.
Vervolgens bestudeerden wij het acute effekt van cortisolinfusie in 3 opklimmende 
doseringen, elk geinfundeerd gedurende een periode van 10 minuten, op de 
onderarmsvaatweerstand. Dit werd verricht voor en tijdens remming van 11 ß-HSD 
activiteit door GA bij personen met een normale en bij personen met een verhoogde 
bloeddruk. Zowel in de groep met normale als in de groep met verhoogde bloeddruk 
leidde infusie van cortisol niet tot een verandering in de onderarmsvaatweerstand, noch 
direkt, noch twee uur na het stoppen van de cortisoltoediening. Ook na remming van
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11 ß-HSD door GA leidde cortisolinfusie niet tot verandering van de 
onderarmsvaatweerstand. Deze gegevens suggereren dat cortisol geen direkt effekt op de 
vaatwandweerstand in de onderarm heeft, noch via niet-gen-gereguleerde, noch via gen- 
gereguleerde mechanismen.
Studies in de nier: bij patienten met hoge bloeddruk werden de rechter nierarterie en — 
vene gecatheriseerd via de lies. Na infusie met glucose 5% gedurende 10 minuten werd 
gestart met infusie van cortisol in drie opklimmende doseringen, elk gedurende 10 
minuten. Aan het eind van elke dosis werd de nierdoorbloeding gemeten met behulp van 
de “133Xenon wash-out” techniek. Infusie van cortisol leidde niet tot een verandering van 
de vaatweerstand in de nier. Een vergelijkbaar protocol werd gevolgd bij een groep 
patienten met hoge bloeddruk bij wie het enzym 11 ß-HSD geremd werd door ongeveer 
150 minuten voor de start van de cortisolinfusie 500 mg GA toe te dienen. Remming van 
de 11 ß-HSD activiteit door GA resulteerde niet in een verandering van de vaatweerstand 
in de nier, noch voor noch tijdens infusie van cortisol. Dit suggereert eveneens dat 
cortisol geen direkt effekt op de vaatweerstand in de nier heeft.
Direkte effecten van cortisolinfusie op de activiteit van de 11ß-HSD isoenzym en in 
de onderarm (hoofdstuk 4) en de nier (hoofdstuk 5), zowel voor als tijdens 
remming van 11ß-HSD
In onze studies werd de activiteit van de 11 ß-HSD isoenzymen in nier of onderarm niet 
direkt gemeten. Wij bepaalden de concentraties van cortisol en cortison in arterieel en 
veneus plasma en berekenden de arteriele en veneuze cortisol/cortison ratios. Deze 
resultaten werden gebruikt als maat voor lokale activiteit van de 11 ß-HSD isoenzymen in 
een bepaald orgaan.
Studies in de onderarm: Eerst werd de lokale activiteit van de 11 ß-HSD isozymen bepaald 
voor en na toediening van GA. Na placebo was er geen significant arterio-veneus verschil 
in de plasmaconcentratie van cortisol of cortison in de onderarm bij individuen met 
normale dan wel verhoogde bloeddruk. Na toediening van GA vonden we ook geen 
significant arterio-veneus verschil in de plasmaconcentratie van cortisol o f cortison in de 
onderarm, zodat er geen aanwijzing was voor lokale activiteit van 11 ß-HSD bij individuen
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met normale dan wel verhoogde bloeddruk. Dit suggereert dat er geen activiteit van de 
11 ß-HSD isozymen in het onderarmsvaatbed is, alhoewel het mogelijk blijft dat hun 
activiteit te gering is om gemeten te kunnen worden door het meten van veranderingen in 
de plasmaconcentratie van cortisol, cortison of de cortisol/cortison ratio van slagader 
naar ader. Toediening van GA leidde wel tot een stijging van de cortisol/cortison ratio in 
arterieel plasma en in speeksel, wijzend op een verminderde activiteit van 11ß-HSD2 
zowel systemisch als ook in de speekselklier, een specifiek doelwitorgaan voor 
mineralocorticoiden. Verder vonden wij geen verschil in de stijging van de 
cortisol/cortison ratio na toediening van GA tussen deelnemers met normale en 
verhoogde bloeddruk, hetgeen er op wijst dat er tussen deze groepen geen verschil is in de 
gevoeligheid van 11 ß-HSD voor GA.
Vervolgens werd de activiteit van de 11 ß-HSD isoenzymen in de onderarm bestudeerd 
tijdens de infusie van cortisol, zowel na toediening van placebo als na toediening van GA. 
Infusie van cortisol resulteerde niet in een toename van de cortison gradient van 
onderarmsslagader naar -ader. Ook deze gegevens pleiten ervoor dat er geen activiteit van 
11ß-HSD2 in de onderarm is.
Studies in de nier: in een groep patienten met primaire hypertensie werden de plasmacon- 
centraties van cortisol en cortison in de bovenbeensslagader en de rechter nierader 
gemeten. Dit gebeurde zowel voor als tijdens infusie van cortisol in de nierslagader. Voor 
de infusie van cortisol was er een toename in de plasmaconcentratie van cortison en een 
afname van de cortisol/cortison ratio van slagader naar nierader. Dit past bij omzetting 
van cortisol in cortison in de nier door 11ß-HSD2. Infusie van cortisol in de nierslagader 
resulteerde in een stijging van de toename van de cortisonconcentratie van slagader naar 
nierader, en in een toegenomen uitscheiding van cortison in de urine. Dit wijst op een 
toegenomen omzetting van cortisol naar cortison door 11ß-HSD2 in de nier tijdens 
cortisolinfusie. Tegelijkertijd was er een verdere toename van de cortisol/cortison ratio in 
de nierader en de urine, suggererend dat de beschikbare reserve capaciteit van 11ß-HSD2 
in de nier onvoldoende was om het extra cortisol adekwaat in cortison om te zetten. Deze 
resultaten wijzen erop dat er tijdens een hoge arteriele aanvoer van cortisol in de 
nierslagader weliswaar een toegenomen produktie van cortison in de nier is, maar dat 
tijdens een toegenomen aanbod van cortisol de omzetting in de nier van cortisol in
130
Samenvatting en conclusies
cortison door 11 ß-HSD2 relatief tekortschiet. D it kan vervolgens leiden tot stimulatie van 
de mineralocorticoidreceptoren in de nier door cortisol.
Toediening van GA leidde tot een toename van de cortisol/cortison ratio in urine. Dit 
wijst er op dat toediening van GA inderdaad resulteerde in remming van de activiteit van 
11ß-HSD2 in de nier. Wij vonden echter geen effekt van GA op de toename van de 
cortisonconcentratie van slagader naar -ader, noch vóór noch tijdens infusie van cortisol. 
Dit wijst er op dat het remmende effekt van GA op de activiteit van 11ß-HSD2 in de nier 
beperkt is. Een alternatieve verklaring is dat de GA dosis te laag was om te leiden tot een 
voldoende remming van de activiteit van 11ß-HSD2 in de nier.
Effect van cortisolinfusie op vrij en eiwit-gebonden fracties van cortison in plasma.
Infusie van cortisol in de armslagader leidde tot een toename van de cortisol/cortison 
ratio in de onderarmsader. Dit was niet alleen het gevolg van de verwachte toename van 
cortisol door de infusie van cortisol in de slagader, maar ook het gevolg van een afname 
van de cortisonconcentratie in veneus plasma in vergelijking met arterieel plasma. Deze 
afname van de veneuze cortisonconcentratie bleek het gevolg te zijn van een afname van 
de aan plasmaeiwitten gebonden fraktie van cortison, niet van een afname van de vrije 
fraktie van cortison. Dit wijst er op dat, in situaties waarin de binding van cortison aan 
corticosteroid-bindend-globuline beinvloed kan worden, veranderingen in de 
cortisol/cortison ratio van arterieel naar veneus plasma geen betrouwbare maat vormen 
voor het inschatten van (veranderingen in) de activiteit van 11 ß-HSD.
11ß-hydroxysteroid dehydrogenase activiteit en vaatwandreactiviteit in de 
onderarm (hoofdstuk 6)
De 11 ß-HSD isoenzymen beinvloeden de lokale contraties van cortisol. Het is bekend dat 
cortisol de vasoconstrictie door noradrenaline verhoogt, de productie van N O  in de 
vaatwand vermindert en de vaatverwijding in de onderarm door acetylcholine doet 
afnemen. Remming van de activiteit van de vasculaire 11 ß-HSDs door carbenoxolon leidt 
ook tot toegenomen vaatvernauwing op noradrenaline. Dit zou veroorzaakt kunnen zijn 
door toegenomen stimulatie van de glucocorticoidreceptoren door cortisol. Wij
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bestudeerden het effekt van remming van 11 ß-HSD activiteit door carbenoxolon op de 
vasculaire reactiviteit in de onderarm bij gezonde mannelijke vrijwilligers met een normale 
bloeddruk. Toediening van carbenoxolon leidde niet tot een verandering van het effekt 
van intra-arteriele toediening van acetylcholine (ACh), natrium nitroprusside (SNP), 
noradrenaline (NA) en N-monomethyl-l-arginine (L-NMMA, een remmer van NO 
synthase). Bij gezonde normotensieve vrijwilligers leidde toediening van carbenoxolon dus 
niet tot toegenomen vasculaire gevoeligheid voor NA en /o f afgenomen gevoeligheid voor 
SNP of ACh. Dit sluit echter niet uit dat langdurige remming van de activiteit van 11 ß- 
HSD de vaatwandspanning zou kunnen beinvloeden.
Conclusies
1. Remming van de activiteit van 11 ß-HSD door glycyrrhetinezuur (GA) leidt niet tot 
een stijging van onderarmsvaatweerstand bij personen met normale o f verhoogde 
bloeddruk en leidt evenmin tot een stijging van de niervaatweerstand bij personen 
met verhoogde bloeddruk.
2. Kortdurende intra-arteriele infusie van cortisol in de onderarm of nier leidt niet 
onmiddellijk tot een stijging van de vaatweerstand in deze organen, noch vóór 
noch tijdens remming van de activiteit van 11 ß-HSD.
3. Activiteit van de 11 ß-HSD isozymen kon niet worden aangetoond in het vaatbed 
van de onderarm, noch bij normotensive noch bij hypertensieve personen.
4. Bij een verhoogd aanbod van cortisol in de nierslagader wordt cortisol in 
verhoogde mate omgezet in cortison in de nier. Bij een toegenomen aanbod van 
cortisol schiet in de nier deze omzetting door 11ß-HSD2 echter relatief tekort.
5. Er zijn geen aanwijzingen voor een verminderde activiteit van 11ß-HSD2 of 
verhoogde gevoeligheid van 11ß-HSD2 voor GA bij patienten met primaire 
hypertensie.
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6. Infusie van cortisol leidt tot een afname van de aan eiwit gebonden fractie van 
cortison in plasma, een afname van de cortisonconcentratie van arterieel naar 
veneus via een orgaan tijdens infusie van cortisol betekent dus niet per se dat er 
activiteit van 11 ß-HSD in dat orgaan is.
7. Bij vrijwilligers met een normale bloeddruk leidt kortdurende remming van 11 ß- 
HSD gedurende 2 dagen niet tot een veranderde reactie van de 
onderarmsbloedvaten op NA, L-NMMA, SNP or ACh.
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